Literature Search Terms

sleep apnea, sleep apnoea, OSA, sleep apnea syndromes, ambulatory, monitoring, polysomnography, snoring, otorhinolaryngologic surgical procedures, surgical procedures, surgery, snoring, obstructive sleep apnea, diagnosis, diagnostic, sleep-related breathing disorders, sleep-disordered breathing, portable, home, limited, unattended, non-laboratory, in-home, out of center, monitor, care service, test, testing, sleep study, screening, recording, device, diagnosed, diagnoses, PSG, polysomnogram, respiratory polygraphy, repeat, retest, retesting, home diagnostic test, multichannel recorder, multi-night, split-night, follow-up, two-night, multiple-night

MeSH Terms

sleep apnea syndromes, sleep apnea obstructive, diagnosis, mass screening, probability, predictive value of tests, adult, ambulatory monitoring, polysomnography, follow-up studies, humans, snoring, otorhinolaryngologic surgical procedures, snoring/surgery, tongue/surgery, diagnostic techniques and procedures

Literature Search Limits

January 1, 2005 to June 29, 2016; Human studies, RCTs or observational studies, adults, English language

Inclusion Criteria

Diagnosis of OSA with PSG, HSAT, oximetry, or clinical prediction algorithm; address one of nine PICO questions, adults, outcomes related to accuracy, inconclusive results, complications, quality of life, medical outcomes, adherence, efficiency of diagnosis or access to care

Exclusion Criteria

Treatment paper, no OSA, pediatric subjects, initial sample size > 25 per condition, 50 total for PICO 2, initial sample size > 10 per condition, 20 total for all other PICOs, wrong publication type (review, editorial, methodological, non-RCT or non-observational study), other sleep comorbidities besides OSA, hospitalized or general surgery, diagnostic test not in PICO question, time between HSAT and PSG > 4 weeks, HSAT used in-lab, HSAT used simultaneously with PSG in-lab, MSLT, MWT, and other nap tests performed

Table S1—Summary of Downstream Consequences of OSA Diagnostic Outcomes

True Positive (TP)

- Effective treatment and improved QOL
- Ineffective treatment and worsening of symptoms
- Increased costs due to treatment
- Time for treatment and follow-up
- Psychological distress
- Side-effects of therapy
- Improvement in comorbid conditions (e.g., hypertension)
- Reduced risk of CV events
- Reduced risk of post-CV events
- Reduced risk of motor vehicle accident (MVA)
- Reduced overall health costs

True Negative (TN)

- Confirmation of absence of OSA
- Possible repeat testing if patient deemed at high risk for OSA
- Psychological relief
- Consideration of alternative causes for symptoms
- Saves time and resources
- Focused treatment on true cause of symptoms

False Positive (FP)

- Unnecessary treatment and utilization of resources
- Increased costs due to treatment
- Time for treatment and follow-up
- Psychological distress
- Delay in diagnosis of true condition
- Side-effects of therapy

False Negative (FN)

- Absence of necessary treatment
- Reduced QOL
- Psychological distress
- Possible repeat testing if patient deemed at high risk for OSA
- Risk of motor vehicle accident (MVA)
- Risk of hypertension
- Risk of CV events
- Post-MI events
- Post-stroke events
- Death
- Increased costs and utilization of resources due to other condition(s)

Diagnosis of obstructive sleep apnea in adults using clinical tools, questionnaires and predication algorithms

Figure S1—Berlin Questionnaire vs. PSG (AHI ≥ 5)

Study	TP	FP	FN	TN	Sensitivity (95% CI)	Specificity (95% CI)	Sensitivity (95% CI)	Specificity (95% CI)
Ahmadi 2008	38	38	18	36	0.68 [0.54, 0.80]	0.49 [0.37, 0.61]		
Amra 2013	121	5	23	8	0.84 [0.77, 0.90]	0.62 [0.32, 0.86]	-	
Bouloukaki 2013	90	6	28	5	0.76 [0.68, 0.84]	0.45 [0.17, 0.77]		
Cowan 2014	89	31	6	3	0.94 [0.87, 0.98]	0.09 [0.02, 0.24]	+	-
Danzi-Soares 2012	44	5	17	4	0.72 [0.59, 0.83]	0.44 [0.14, 0.79]		
Friedman 2010	120	49	41	13	0.75 [0.67, 0.81]	0.21 [0.12, 0.33]	+	
Kang 2013	44	6	21	30	0.68 [0.55, 0.79]	0.83 [0.67, 0.94]		
Khaledi-Paveh 2016	60	17	18	5	0.77 [0.66, 0.86]	0.23 [0.08, 0.45]		
Kim 2015	356	66	139	31	0.72 [0.68, 0.76]	0.32 [0.23, 0.42]	•	
Laporta 2012	56	14	12	9	0.82 [0.71, 0.91]	0.39 [0.20, 0.61]		
Luo 2014	130	4	65	13	0.67 [0.60, 0.73]	0.76 [0.50, 0.93]	-	
Margallo 2014	236	42	110	34	0.68 [0.63, 0.73]	0.45 [0.33, 0.57]	-	
Pataka 2014	1260	222	241	130	0.84 [0.82, 0.86]	0.37 [0.32, 0.42]		+
Pereira 2013	100	9	16	3	0.86 [0.79, 0.92]	0.25 [0.05, 0.57]	-	
Popevic 2016	30	6	28	36	0.52 [0.38, 0.65]	0.86 [0.71, 0.95]		
Rofail 2010	105	35	28	17	0.79 [0.71, 0.86]	0.33 [0.20, 0.47]	-	
Sarinc Ulasi 2013	986	58	362	44	0.73 [0.71, 0.75]	0.43 [0.33, 0.53]		
Sert Kuniyoshi 2011	47	16	22	14	0.68 [0.56, 0.79]	0.47 [0.28, 0.66]		
Suksakorn 2014	87	8	13	24	0.87 [0.79, 0.93]	0.75 [0.57, 0.89]		
							0 0.2 0.4 0.6 0.8 1	0 0.2 0.4 0.6 0.8 1

Pooled sensitivity: 0.76 [0.72, 0.80] **Pooled specificity:** 0.45 [0.34, 0.56] LR+: 1.38 [1.15, 1.66] LR-: 0.53 [0.42, 0.65] DOR: 2.63 [1.79, 3.86] Accuracy: 0.70 or 70%






Table S2—Summary of Findings table for Berlin Questionnaire vs. PSG to diagnose OSA in Suspected Adults (AHI \ge 5)

References: Ahmadi 2008 (A); Amra 2013 (B); Bouloukaki 2013 (C); Danzi-Soares 2012 (D); Friedman 2010 (E); Kang 2013 (F); Laporta 2012 (G); Pereira 2013 (H); Rofail 2010 (I); Sarinc Ulasi 2013 (J); Sert Kuniyoshi 2011 (K); Cowan 2014 (L); Khaledi-Paveh 2016 (M); Kim 2015 (N); Luo 2014 (O); Margallo 2014 (P); Pataka 2014 (Q); Popevic 2016 R; Suksakorn 2014 (S)

Pooled sensitivity Berlin Questionnaire: 0.76 (95% CI: 0.72 to 0.80) | Pooled specificity Berlin Questionnaire: 0.45 (95% CI: 0.34 to 0.56) Pooled sensitivity Attended PSG: 1.00 (95% CI: 1.00 to 1.00) | Pooled specificity Attended PSG: 1.00 (95% CI: 1.00 to 1.00) | Pooled specificity Attended PSG: 1.00 (95% CI: 1.00 to 1.00) | Accuracy (high risk): 72% (95% CI: 70 to 74%) Accuracy (low risk): 62% (95% CI: 60 to 64%)


		Number of res	d (95% CI)				
Test result	Quality of the	Prevalen	ce 87%	Prevalenc	Number of participants		
	Evidence (GRADE)	Berlin Questionnaire	Attended PSG	Berlin Questionnaire	Attended PSG	(studies)	
True positives (patients with OSA)		661 (626 to 696)	870 (870 to 870)	418 (396 to 440)	550 (550 to 550)		
	$\oplus \oplus \bigcirc \bigcirc$	209 fewer TP in Questionnaire	n Berlin	132 fewer TP i Questionnaire		6303	
False negatives	LOW ^{1,2}	209 (174 to 244)	0 (0 to 0)	132 (110 to 154)	0 (0 to 0)	(19) ^{A-S}	
(patients incorrectly classified as not having OSA)		209 more FN in Berlin Questionnaire		132 more FN i Questionnaire			
True negatives		59 (44 to 73)	130 (130 to 130)	202 (153 to 252)	450 (450 to 450)		
(patients without OSA)	$\oplus \oplus \bigcirc \bigcirc$	71 fewer TN in Berlin Questionnaire		248 fewer TN i Questionnaire	6303		
False positives	LOW ^{1,2}	71 (57 to 86)	0 (0 to 0)	248 (198 to 297)	0 (0 to 0)	(19) ^{A-S}	
(patients incorrectly classified as having OSA)		71 more FP in Berlin Questionnaire		248 more FP in Questionnaire			

²Wide confidence intervals

Figure S3—Berlin Questionnaire vs. PSG (AHI ≥ 15)

Study	TP	FP	FN	TN	Sensitivity (95% CI)	Specificity (95% CI)	Sensitivity (95% CI)	Specificity (95% CI)
Ahmadi 2008	16	60	12	42	0.57 [0.37, 0.76]	0.41 [0.32, 0.51]		
Amra 2013	95	32	13	17	0.88 [0.80, 0.93]	0.35 [0.22, 0.50]		
Bouloukaki 2013	83	12	15	19	0.85 [0.76, 0.91]	0.61 [0.42, 0.78]		
Cowan 2014	53	66	4	6	0.93 [0.83, 0.98]	0.08 [0.03, 0.17]	-	+-
Danzi-Soares 2012	28	21	10	11	0.74 [0.57, 0.87]	0.34 [0.19, 0.53]		
Firat 2012	21	6	25	33	0.46 [0.31, 0.61]	0.85 [0.69, 0.94]		
Friedman 2010	35	29	114	45	0.23 [0.17, 0.31]	0.61 [0.49, 0.72]	-	
Kang 2013	34	23	4	40	0.89 [0.75, 0.97]	0.63 [0.50, 0.75]		
Khaledi-Paveh 2016	32	25	22	21	0.59 [0.45, 0.72]	0.46 [0.31, 0.61]		
Kim 2015	260	160	83	89	0.76 [0.71, 0.80]	0.36 [0.30, 0.42]	+	+
Margallo 2014	160	114	72	76	0.69 [0.63, 0.75]	0.40 [0.33, 0.47]	-	
Pataka 2014	1093	408	168	204	0.87 [0.85, 0.89]	0.33 [0.30, 0.37]	•	+
Pereira 2013	80	29	8	11	0.91 [0.83, 0.96]	0.28 [0.15, 0.44]		
Sarinc Ulasi 2013	769	261	246	174	0.76 [0.73, 0.78]	0.40 [0.35, 0.45]	•	+
Sert Kuniyoshi 2011	30	34	16	19	0.65 [0.50, 0.79]	0.36 [0.23, 0.50]		0 0.2 0.4 0.6 0.8 1

Pooled sensitivity: 0.75 [0.64, 0.83] Pooled specificity: 0.42 [0.32, 0.52] LR+: 1.29 [1.12, 1.48] LR-: 0.60 [0.44, 0.81] DOR: 2.16 [1.42, 3.27] Accuracy: 0.63 or <u>63%</u>






Table S3—Summary of Findings table for Berlin Questionnaire vs. PSG to diagnose OSA in Suspected Adults (AHI \ge 15)

References: Ahmadi 2008 (A); Amra 2013 (B); Bouloukaki 2013 (C); Danzi-Soares 2012 (D); Friedman 2010 (E); Kang 2013 (F); Pereira 2013 (G); Sarinc Ulasi 2013 (H); Sert Kuniyoshi 2011 (I); Cowan 2014 (J); Khaledi-Paveh 2016 (K); Kim 2015 (L); Margallo 2014 (M); Pataka 2014 (N); Firat 2012 (O)

Pooled sensitivity Berlin Questionnaire: 0.75 (95% CI: 0.64 to 0.83) | **Pooled specificity Berlin Questionnaire:** 0.42 (95% CI: 0.32 to 0.52) **Pooled sensitivity Attended PSG:** 1.00 (95% CI: 1.00 to 1.00) | **Pooled specificity Attended PSG:** 1.00 (95% CI: 1.00 to 1.00) | **Pooled specificity Attended PSG:** 1.00 (95% CI: 1.00 to 1.00) | **Pooled specificity Attended PSG:** 1.00 (95% CI: 1.00 to 1.00) | **Pooled specificity Attended PSG:** 1.00 (95% CI: 1.00 to 1.00) | **Pooled specificity Attended PSG:** 1.00 (95% CI: 1.00 to 1.00) | **Pooled specificity Attended PSG:** 1.00 (95% CI: 1.00 to 1.00) | **Pooled specificity Attended PSG:** 1.00 (95% CI: 1.00 to 1.00) | **Pooled specificity Attended PSG:** 1.00 (95% CI: 1.00 to 1.00) | **Pooled specificity Attended PSG:** 1.00 (95% CI: 1.00 to 1.00) | **Pooled specificity Attended PSG:** 1.00 (95% CI: 1.00 to 1.00) | **Pooled specificity Attended PSG:** 1.00 (95% CI: 1.00 to 1.00) | **Pooled specificity Attended PSG:** 1.00 (95% CI: 1.00 to 1.00) | **Pooled specificity Attended PSG:** 1.00 (95% CI: 1.00 to 1.00) | **Pooled specificity Attended PSG:** 1.00 (95% CI: 1.00 to 1.00) | **Pooled specificity Attended PSG:** 1.00 (95% CI: 1.00 to 1.00) | **Pooled specificity Attended PSG:** 1.00 (95% CI: 1.00 to 1.00) | **Pooled specificity Attended PSG:** 1.00 (95% CI: 1.00 to 1.00) | **Pooled specificity Attended PSG:** 1.00 (95% CI: 1.00 to 1.00) | **Pooled specificity Attended PSG:** 1.00 (95% CI: 1.00 to 1.00) | **Pooled specificity Attended PSG:** 1.00 (95% CI: 1.00 to 1.00) | **Pooled specificity Attended PSG:** 1.00 (95% CI: 1.00 to 1.00) | **Pooled specificity Attended PSG:** 1.00 (95% CI: 1.00 to 1.00) | **Pooled specificity Attended PSG:** 1.00 (95% CI: 1.00 to 1.00) | **Pooled specificity Attended PSG:** 1.00 (95% CI: 1.00 to 1.00) | **Pooled specificity Attended PSG:** 1.00 to 1.00 | **Pooled specificity Attende**

	-	Number of res	d (95% CI)			
Test result	Quality of the	Prevalen	ce 64%	Prevalenc	Number of participants	
	Evidence (GRADE)	Berlin Questionnaire	Attended PSG	Berlin Questionnaire	Attended PSG	(studies)
True positives (patients with OSA)		480 (410 to 531)	640 (640 to 640)	188 (160 to 208)	250 (250 to 250)	
	$\Theta \Theta \bigcirc \bigcirc$	160 fewer TP in Berlin Questionnaire		62 fewer TP in Questionnaire		5668
False negatives (patients incorrectly classified as not having OSA)	LOW ^{1,2}	160 (109 to 230)	0 (0 to 0)	62 (42 to 90)	0 (0 to 0)	(15) ^{A-O}
		209 more FN in Berlin Questionnaire		62 more FN in Questionnaire		
True negatives		151 (115 to 187)	360 (360 to 360)	315 (240 to 390)	750 (750 to 750)	
(patients without OSA)	$\oplus \oplus \bigcirc \bigcirc$	209 fewer TN in Berlin Questionnaire		435 fewer TN i Questionnaire	5668	
False positives	LOW ^{1,2}	209 (173 to 245)	0 (0 to 0)	435 (360 to 510)	0 (0 to 0)	(15) ^{A-O}
(patients incorrectly classified as having OSA)		209 more FP in Berlin Questionnaire		435 more FP i Questionnaire		
Broad range of specificity across Wide confidence intervals	studies					

Figure S5—Berlin Questionnaire vs. PSG (AHI ≥ 30)

Study	ТР	FP	FN	TN	Sensitivity (95% CI)	Specificity (95% CI)	Sensitivity (95% CI)	Specificity (95% CI)
Amra 2013	65	61	9	22	0.88 [0.78, 0.94]	0.27 [0.17, 0.37]		
Bouloukaki 2013	54	37	14	24	0.79 [0.68, 0.88]	0.39 [0.27, 0.53]		
Friedman 2010	67	49	29	78	0.70 [0.60, 0.79]	0.61 [0.52, 0.70]		
Pataka 2014	811	681	88	273	0.90 [0.88, 0.92]	0.29 [0.26, 0.32]	•	•
Pereira 2013	50	59	6	13	0.89 [0.78, 0.96]	0.18 [0.10, 0.29]		
Sarinc Ulasi 2013	487	547	122	294	0.80 [0.77, 0.83]	0.35 [0.32, 0.38]	•	•
Sert Kuniyoshi 2011	15	49	6	29	0.71 [0.48, 0.89]	0.37 [0.26, 0.49]		

Pooled sensitivity: 0.84 [0.77, 0.89] Pooled specificity: 0.35 [0.26, 0.44] DOR: 2.73 [2.11, 3.52] LR+: 1.28 [1.17, 1.41] LR-: 0.47 [0.38, 0.58] Accuracy: 0.56 or <u>56%</u>




Figure S6—ROC Curve for Berlin Questionnaire vs. PSG (AHI \ge 30)

Table S4—Summary of Findings table for Berlin Questionnaire vs. PSG to diagnose OSA in Suspected Adults (AHI \ge 30)

References: Amra 2013 (A); Bouloukaki 2013 (B); Friedman 2010 (C); Pereira 2013 (D); Sarinc Ulasi 2013 (E); Sert Kuniyoshi 2011 (F); Pataka 2014 (G)

Pooled sensitivity Berlin Questionnaire: 0.84 (95% CI: 0.77 to 0.89) | **Pooled specificity Berlin Questionnaire:** 0.35 (95% CI: 0.26 to 0.44) **Pooled sensitivity Attended PSG:** 1.00 (95% CI: 1.00 to 1.00) | **Pooled specificity Attended PSG:** 1.00 (95% CI: 1.00 to 1.00) | **Pooled specificity Attended PSG:** 1.00 (95% CI: 1.00 to 1.00) | **Pooled specificity Attended PSG:** 1.00 (95% CI: 1.00 to 1.00) | **Pooled specificity Attended PSG:** 1.00 (95% CI: 1.00 to 1.00) | **Pooled specificity Attended PSG:** 1.00 (95% CI: 1.00 to 1.00) | **Pooled specificity Attended PSG:** 1.00 (95% CI: 1.00 to 1.00) | **Pooled specificity Attended PSG:** 1.00 (95% CI: 1.00 to 1.00) | **Pooled specificity Attended PSG:** 1.00 (95% CI: 1.00 to 1.00) | **Pooled specificity Attended PSG:** 1.00 (95% CI: 1.00 to 1.00) | **Pooled specificity Attended PSG:** 1.00 (95% CI: 1.00 to 1.00) | **Pooled specificity Attended PSG:** 1.00 (95% CI: 1.00 to 1.00) | **Pooled specificity Attended PSG:** 1.00 (95% CI: 1.00 to 1.00) | **Pooled specificity Attended PSG:** 1.00 (95% CI: 1.00 to 1.00) | **Pooled specificity Attended PSG:** 1.00 (95% CI: 1.00 to 1.00) | **Pooled specificity Attended PSG:** 1.00 (95% CI: 1.00 to 1.00) | **Pooled specificity Attended PSG:** 1.00 (95% CI: 1.00 to 1.00) | **Pooled specificity Attended PSG:** 1.00 (95% CI: 1.00 to 1.00) | **Pooled specificity Attended PSG:** 1.00 (95% CI: 1.00 to 1.00) | **Pooled specificity Attended PSG:** 1.00 (95% CI: 1.00 to 1.00) | **Pooled specificity Attended PSG:** 1.00 (95% CI: 3.00 to 1.00) | **Pooled specificity Attended PSG:** 1.00 (95% CI: 3.00 to 1.00) | **Pooled specificity Attended PSG:** 1.00 (95% CI: 3.00 to 1.00) | **Pooled specificity Attended PSG:** 1.00 (95% CI: 3.00 to 1.00) | **Pooled specificity Attended PSG:** 1.00 to 1.00 | **Pooled specificity Attended PSG:** 1.00 to

		Number of res	d (95% CI)			
Test result	Quality of the	Prevalen	ce 36%	Prevalenc	Number of participants	
	Evidence (GRADE)	Berlin Questionnaire	Attended PSG	Berlin Questionnaire	Attended PSG	(studies)
True positives (patients with OSA) False negatives		302 (277 to 320)	360 (360 to 360)	84 (77 to 89)	100 (100 to 100)	
	$\oplus \oplus \bigcirc \bigcirc$	58 fewer TP in Berlin Questionnaire		16 fewer TP in Berlin Questionnaire		4039 (7) ^{A-G}
	LOW ^{1,2}	58 (40 to 83)	0 (0 to 0)	16 (11 to 23)	0 (0 to 0)	(7)
(patients incorrectly classified as not having OSA)		58 more FN in Berlin Questionnaire		16 more FN in Questionnaire		
True negatives		224 (166 to 282)	640 (640 to 640)	315 (234 to 396)	900 (900 to 900)	
(patients without OSA)	$\oplus \oplus \bigcirc \bigcirc$	416 fewer TN in Berlin Questionnaire		585 fewer TN i Questionnaire		4039
False positives	LOW ^{1,2}	416 (358 to 474)	0 (0 to 0)	585 (504 to 666)	0 (0 to 0)	(7) ^{A-G}
(patients incorrectly classified as having OSA)		416 more FP in Berlin Questionnaire		585 more FP in Questionnaire		

²Wide confidence intervals

Table S5—Summary of Findings table for Berlin Questionnaire vs. Home Sleep Apnea Test (HSAT) to diagnose OSA in Suspected Adults (AHI \ge 5)

References: Facco 2012 (A)

Single study sensitivity Berlin Questionnaire: 0.39 (95% Cl: 0.22 to 0.59) | Single study specificity Berlin Questionnaire: 0.68 (95% Cl: 0.56 to 0.78) |Single study sensitivity HSAT: 1.00 (95% Cl: 1.00 to 1.00) | Single study specificity HSAT: 1.00 (95% Cl: 1.00 to 1.00) Accuracy high risk: 43% (95% Cl: 26 to 61%) Accuracy low risk: 52% (95% Cl: 37 to 68%)

		Number of					
Test result	Quality of the Evidence	Prevaler	nce 87%	Prevale	Prevalence 55%		
	(GRADE)	Berlin Questionnaire	HSAT	Berlin Questionnair e	HSAT	 participants (studies) 	
True positives (patients with OSA) False negatives (patients incorrectly		339 (191 to 513)	870 (870 to 870)	215 (121 to 325)	550 (550 to 550)		
	$\oplus \oplus \bigcirc \bigcirc$	531 fewer TP in Berlin Questionnaire		335 fewer TP in Berlin Questionnaire		100	
	LOW ^{1,2}	531 (679 to 357)	0 (0 to 0)	335 (429 to 225)	0 (0 to 0)	(1) ^A	
classified as not having OSA)		531 more FN in Berlin Questionnaire		335 more FN Questionnair			
True negatives		88 (73 to 101)	130 (130 to 130)	306 (252 to 351)	450 (450 to 450)		
(patients without OSA)	$\oplus \oplus \bigcirc \bigcirc$	42 fewer TN in Berlin Questionnaire			144 fewer TN in Berlin Questionnaire		
False positives (patients incorrectly	LOW ^{1,2}	42 (57 to 29)	0 (0 to 0)	144 (198 to 99)	0 (0 to 0)	(1) ^A	
classified as having OSA)		42 more FP in Berlin Questionnaire		144 more FP Questionnair			

²Wide confidence interval for sensitivity and specificity

Figure S7—Berlin Questionnaire vs. HSAT (AHI ≥ 15)

Study	ТР	FP	FN	TN	Sensitivity (95% CI)	Specificity (95% CI)	Sensitivity (95% CI)	Specificity (95% CI)
Gantner 2010	88	29	11	15	0.89 [0.81, 0.94]	0.34 [0.20, 0.50]		
Nicholl 2013	109	45	- 7	23	0.94 [0.88, 0.98]	0.34 [0.23, 0.46]	-	
Nicholl 2013	63	19	10	12	0.86 [0.76, 0.93]	0.39 [0.22, 0.58]		
Sforza 2011	283	167	84	109	0.77 [0.72, 0.81]	0.39 [0.34, 0.46]	+	-
Simpson 2013	63	198	56	476	0.53 [0.44, 0.62]	0.71 [0.67, 0.74]		

Pooled sensitivity: 0.76 [0.64, 0.85] Pooled specificity: 0.44 [0.30, 0.58] LR+: 1.36 [0.91, 2.02] LR-: 0.54 [0.26, 1.20] DOR: 2.31 [1.68, 2.42] Accuracy: 0.67 or <u>67%</u>

Table S6—Summary of Findings table for Berlin Questionnaire vs. HSAT to diagnose OSA in Suspected Adult (AHI \ge 15)

References: Gantner 2010 (A); Nicholl 2013 (B); Sforza 2011 (C); Simpson 2013 (D)

Pooled sensitivity Berlin Questionnaire: 0.76 (95% CI: 0.44 to 0.85) | Pooled specificity Berlin Questionnaire: 0.44 (95% CI: 0.30 to 0.58) Pooled sensitivity Attended PSG: 1.00 (95% CI: 1.00 to 1.00) | Pooled specificity Attended PSG: 1.00 (95% CI: 1.00 to 1.00) | Pooled specificity Attended PSG: 1.00 (95% CI: 1.00 to 1.00) | Accuracy (high risk): 53% (95% CI: 52 to 53%) Accuracy (low risk): 40% (95% CI: 38 to 42%)

		Number of res	d (95% CI)				
Test result	Quality of the	Prevalence	ce 64%	Prevalenc	Number of participants		
	Evidence (GRADE)	Berlin Questionnaire	HSAT	Berlin Questionnaire	HSAT	(studies)	
True positives (patients with OSA)		486 (282 to 544)	640 (640 to 640)	190 (110 to 213)	250 (250 to 250)		
	$\oplus \oplus \bigcirc \bigcirc$	154 fewer TP in Berlin Questionnaire		60 fewer TP in Berlin Questionnaire		1751	
False negatives	LOW ^{1,2}	154 (96 to 358)	0 (0 to 0)	60 (37 to 140)	0 (0 to 0)	(4) ^{A-D}	
(patients incorrectly classified as not having OSA)		154 more FN in Berlin Questionnaire		60 more FN in Questionnaire			
True negatives		158 (108 to 209)	360 (360 to 360)	330 (225 to 435)	750 (750 to 750)		
(patients without OSA)	$\oplus \oplus \bigcirc \bigcirc$	202 fewer TN in Berlin Questionnaire		420 fewer TN i Questionnaire		1751	
False positives	LOW ^{1,2}	202 (151 to 252)	0 (0 to 0)	420 (315 to 525)	0 (0 to 0)	(4) ^{A-D}	
(patients incorrectly classified as having OSA)		202 more FP in Berlin Questionnaire		420 more FP in Questionnaire			

¹Broad range of specificity and sensitivity across studies ²Wide confidence intervals

Table S7—Berlin Questionnaire vs. HSAT to diagnose OSA in Suspected Adults (AHI \ge 30)

References: Gantner 2010 (A); Nicoll 2013 (B)

Range of sensitivities Berlin Questionnaire: 0.76 to 0.92 | Range of specificities Berlin Questionnaire: 0.26 to 0.42 Range of sensitivities HSAT: 1.00 to 1.00 | Range of specificities HSAT: 1.00 to 1.00 Accuracy (high risk): 44% to 60% Accuracy (low risk): 31% to 47%

		Number of rea	Number of results per 1000 patients tested (95% CI)					
Test result	Quality of the Evidence (GRADE)	Prevalence	ce 36%	Prevalence	Number of participants			
	, , ,	Berlin Questionnaire	HSAT	Berlin Questionnaire	HSAT	- (studies)		
True positives		274 to 331	360 to 360	76 to 92	100 to 100			
(patients with OSA)	$\oplus \oplus \bigcirc \bigcirc$	29 to 86 fewer TP in Berlin Questionnaire		8 to 24 fewer TP in Berlin Questionnaire		315 (2) ^{A,B}		
False negatives	LOW ^{1,2}	86 to 29	0 to 0	24 to 8	0 to 0	- (2) , , , , , , , , , , , , , , , , , , ,		
(patients incorrectly classified as not having OSA)		29 to 86 more FN in Berlin Questionnaire		8 to 24 more F Berlin Questic				
T		166 to 269	640 to 640	234 to 378	900 to 900			
True negatives (patients without OSA)	$\Theta \Theta \odot \odot$	371 to 474 fewer TN in Berlin Questionnaire		666 fewer to 522 fewer TN in Berlin Questionnaire		315		
	LOW ^{1,2}	371 to 474	0 to 0	522 to 666	0 to 0	- (2) ^{A,B}		
False positives (patients incorrectly classified as having OSA)		371 to 474 fewer TP in Berlin Questionnaire		522 to 666 fewer TP in Berlin Questionnaire				

¹Indirect evidence as Berlin Questionnaire was not compared against HSAT in any of the PICO questions ²Wide range of sensitivity and specificity across studies

Table S8—Summary of Findings table for ESS vs. PSG to diagnose OSA in Suspected Adults (AHI \geq 5)

References: Chen 2011 (A); Danzi-Soares (B); Zou 2013 (C); Sarinc Ulasli 2013 (D); Pataka 2014 (E); Luo 2014 (F)

Range of sensitivities Epworth Sleepiness Scale: 0.27 to 0.72 | Range of specificities Epworth Sleepiness Scale: 0.50 to 0.76 | Range of sensitivities Attended PSG: 1.00 to 1.00 | Accuracy (high risk): (51% to 52%) Accuracy (low risk): (54% to 59%)

		Number					
Test result	Quality of the Evidence	Preval	ence 87%	Preval	Number of participants		
	(GRADE)	ESS	Attended PSG	ESS	Attended PSG	(studies)	
True positivos		235 to 626	870 to 870	149 to 396	550 to 550		
True positives (patients with OSA)	$\oplus \oplus \bigcirc \bigcirc$	244 to 635 fewer TP in ESS		154 to 401 fewer TP in ESS		4724	
False negatives (patients incorrectly classified as not having OSA)	LOW ^{1,2}	244 to 635	0 to 0	154 to 401	0 to 0	(6) ^{A-F}	
		244 to 635 more FN in ESS		154 to 401 m			
True negatives		65 to 99	130 to 130	225 to 342	450 to 450		
(patients without OSA) False positives		31 to 65 fev	31 to 65 fewer TN in ESS		108 to 225 fewer TN in ESS		
	⊕⊕⊖⊖ LOW ^{1,2}	31 to 65	0 to 0	108 to 225	0 to 0	- 4724 (6) ^{A-F}	
(patients incorrectly classified as having OSA)		31 to 65 more FP in ESS		108 to 225 m			

²Wide confidence intervals for sensitivity and specificity

Table S9—Summary of Findings table for ESS vs. PSG to diagnose OSA in Suspected Adults (AHI \ge 15)

References: Danzi-Soares (A); Subramanian 2011 (B); Ulasli 2014 (C); Pataka 2014 (D); Luo 2014 (E)

Range of sensitivities ESS: 0.21 to 0.58 | Range of specificities ESS: 0.50 to 0.72 Range of sensitivities Attended PSG: 1.00 to 1.00 | Range of specificities Attended PSG: 1.00 to 1.00 Accuracy (high risk): 46% to 48% Accuracy (low risk): 54% to 58%

	Quality of	Number of					
Test result	the	Prevalen	ce 64%	Preva	Number of participants		
	Evidence (GRADE)	ESS	Attended PSG	ESS	Attended PSG	(studies)	
True positives		134 to 371	640 to 640	53 to 143	250 to 250		
(patients with OSA)		269 to 506 fewer	TP in ESS	105 to 197 fe	wer TP in ESS	4002	
False negatives	⊕⊕⊖⊖ LOW ^{1,2}	269 to 506	0 to 0	105 to 197	0 to 0	- 4093 (5) ^{A-E}	
(patients incorrectly classified as not having OSA)		269 to 506 more	FN in ESS	105 to 197 m			
True negatives		180 to 259	360 to 360	375 to 540	750 to 750		
(patients without OSA)		101 to 180 fewer	101 to 180 fewer TN in ESS		210 to 375 fewer TN in ESS		
False positives	⊕⊕⊖⊖ LOW ^{1,2}	101 to180	0 to 0	201 to 375	0 to 0	– 4093 (5) ^{A-E}	
(patients incorrectly classified as having OSA)		101 to 180 more FP in ESS		201 to 375 m			

²Confidence interval for studies is wide

Table S10—Summary of Findings table for ESS vs. PSG to diagnose OSA in Suspected Adults (AHI \ge 30)

References: Ulasli 2014 (A); Pataka 2014 (B); Luo 2014 (C)

Range of sensitivities ESS: 0.53 to 0.63 | Range of specificities ESS: 0.54 to 0.62 Range of sensitivities Attended PSG: 1.00 to 1.00 | Range of specificities Attended PSG: 1.00 to 1.00 Accuracy (high risk): 46% to 48% Accuracy (low risk): 54% to 58%

	Quality of	Number of	Number of				
Test result	the	Prevalen	ce 36%	Preva	Prevalence 10%		
	Evidence (GRADE)	ESS	Attended PSG	ESS	Attended PSG	(studies)	
True positives		191 to 227	360 to 360	53 to 63	100 to 100		
(patients with OSA)	0000	133 to 169 fewe	r TP in ESS	37 to 47 fewe	37 to 47 fewer TP in ESS		
False negatives (patients incorrectly classified as not having OSA)	⊕⊕⊕⊕ HIGH	133 to 169	0 to 0	37 to 47	0 to 0	3515 (3) ^{A-C}	
		133 to 169 more	FN in ESS	105 to 197 m			
True negatives		346 to 397	640 to 640	486 to 558	900 to 900		
(patients without OSA)		243 to 294 fewe	r TN in ESS	342 to 414 fe	0545		
False positives (patients incorrectly classified as having OSA)	⊕⊕⊕⊕ HIGH	243 to 294	0 to 0	342 to 414	0 to 0	- 3515 (3) ^{A-C}	
		243 to 294 more FP in ESS		342 to 414 m			

Table S11—Summary of Findings table for ESS vs. HSAT to diagnose OSA in Suspected Adults (AHI \ge 5)

References: Facco 2012 (A)

Single study sensitivity ESS: 0.36 (95% CI: 0.19 to 0.57) | Single study specificity ESS: 0.77 (95% CI: 0.66 to 0.86) Single study sensitivity HSAT: 1.00 (95% CI: 1.00 to 1.00) | Single study specificity HSAT: 1.00 (95% CI: 1.00 to 1.00) | Single study specificity HSAT: 1.00 (95% CI: 1.00 to 1.00) | Single study specificity HSAT: 1.00 (95% CI: 1.00 to 1.00) | Single study specificity HSAT: 1.00 (95% CI: 1.00 to 1.00) | Single study specificity HSAT: 1.00 (95% CI: 1.00 to 1.00) | Single study specificity HSAT: 1.00 (95% CI: 1.00 to 1.00) | Single study specificity HSAT: 1.00 (95% CI: 1.00 to 1.00) | Single study specificity HSAT: 1.00 (95% CI: 1.00 to 1.00) | Single study specificity HSAT: 1.00 (95% CI: 1.00 to 1.00) | Single study specificity HSAT: 1.00 (95% CI: 1.00 to 1.00) | Single study specificity HSAT: 1.00 (95% CI: 1.00 to 1.00) | Single study specificity HSAT: 1.00 (95% CI: 1.00 to 1.00) | Single study specificity HSAT: 1.00 (95% CI: 1.00 to 1.00) | Single study specificity HSAT: 1.00 (95% CI: 1.00 to 1.00) | Single study specificity HSAT: 1.00 (95% CI: 1.00 to 1.00) | Single study specificity HSAT: 1.00 (95% CI: 1.00 to 1.00) | Single study specificity HSAT: 1.00 (95% CI: 1.00 to 1.00) | Single study specificity HSAT: 1.00 (95% CI: 1.00 to 1.00) | Single study specificity HSAT: 1.00 (95% CI: 1.00 to 1.00) | Single study specificity HSAT: 1.00 (95% CI: 1.00 to 1.00) | Single study specificity HSAT: 1.00 (95% CI: 1.00 to 1.00) | Single study specificity HSAT: 1.00 (95% CI: 1.00 to 1.00) | Single study specificity HSAT: 1.00 (95% CI: 1.00 to 1.00) | Single study specificity HSAT: 1.00 (95% CI: 1.00 to 1.00) | Single study specificity HSAT: 1.00 (95% CI: 1.00 to 1.00) | Single study specificity HSAT: 1.00 (95% CI: 1.00 to 1.00) | Single study specificity HSAT: 1.00 (95% CI: 1.00 to 1.00) | Single study specificity HSAT: 1.00 (95% CI: 1.00 to 1.00) | Single study specificity sp


Test result	Quality of the	Number o	Number of				
	Evidence	Prevale	nce 87%	Preval	Prevalence 55%		
	(GRADE)	ESS	HSAT	ESS	HSAT	— (studies)	
True positives	_	313 (165 to 496)	870 (870 to 870)	198 (105 to 314)	550 (550 to 550)		
(patients with OSA)	$\oplus \oplus \bigcirc \bigcirc$	557 fewer TP i	n ESS	352 fewer TP	in ESS	100	
False negatives (patients incorrectly	LOW ^{1,2}	557 (374 to 705)	0 (0 to 0)	352 (236 to 445)	0 (0 to 0)	(1) ^A	
classified as not having OSA)		557 more FN i	n ESS	352 more FN	352 more FN in ESS		
True negatives (patients without		100 (86 to 112)	130 (130 to 130)	347 (297 to 387)	450 (450 to 450)		
ÖSA)	⊕⊕⊖⊖ LOW ^{1,2}	30 fewer TN in	ESS	103 fewer TN	103 fewer TN in ESS		
False positives (patients incorrectly classified as having OSA)		30 (18 to 44)	0 (0 to 0)	103 (63 to 153)	0 (0 to 0)	(1) A	
		30 more FP in	ESS	103 more FP	[

²Wide confidence interval for sensitivity and specificity

Figure S8—STOP-BANG Questionnaire vs. PSG to diagnose OSA in Suspected Adults (AHI \geq 5)

Study	TP	FP	FN	TN	Sensitivity (95% CI)	Specificity (95% CI)	Sensitivity (95% CI)	Specificity (95% CI)
Alhouqani 2015	149	19	15	10	0.91 [0.85, 0.95]	0.34 [0.18, 0.54]	-	
BaMammam 2015	92	5	2	1	0.98 [0.93, 1.00]	0.17 [0.00, 0.64]	-	
Banhiran 2014	194	42	28	39	0.87 [0.82, 0.91]	0.48 [0.37, 0.60]	-	
Cowan 2014	92	23	- 5	9	0.95 [0.88, 0.98]	0.28 [0.14, 0.47]	-	
Kim 2015	480	- 77	17	18	0.97 [0.95, 0.98]	0.19 [0.12, 0.28]		
Luo 2014	186	8	10	8	0.95 [0.91, 0.98]	0.50 [0.25, 0.75]	-	
Ong 2010	201	38	37	43	0.84 [0.79, 0.89]	0.53 [0.42, 0.64]	+	
Pataka 2014	1311	329	70	143	0.95 [0.94, 0.96]	0.30 [0.26, 0.35]		•
Pereira 2013	104	- 7	12	5	0.90 [0.83, 0.95]	0.42 [0.15, 0.72]	+	
Sadeghniiat-Haghighi 2015	404	90	36	73	0.92 [0.89, 0.94]	0.45 [0.37, 0.53]		

Pooled sensitivity: 0.93 [0.90, 0.95] Pooled specificity: 0.36 [0.29, 0.44] LR+: 1.46 [1.32, 1.62] LR-: 0.19 [0.16, 0.23] DOR: 7.72 [6.35, 9.39] Accuracy: 0.80 or <u>80%</u>






Table S12—Summary of Findings table for STOP-BANG Questionnaire vs. PSG to diagnose OSA in Suspected Adults (AHI \ge 5)

References: Alouqani 2015 (A); BaHammam 2015 (B); Banhiran 2014 (C); Cowan 2014 (D); Kim 2015 (E); Luo 2014 (F); Ong 2010 (G); Pataka 2014 (H); Pereira 2013 (I); Sadeghniiat-Highighi 2015 (J)

Pooled sensitivity STOP-BANG Questionnaire: 0.93 (95% Cl: 0.90 to 0.95) | **Pooled specificity STOP-BANG Questionnaire:** 0.36 (95% Cl: 0.29 to 0.44) **Pooled sensitivity Attended PSG:** 1.00 (95% Cl: 1.00 to 1.00) | **Pooled specificity Attended PSG:** 1.00 (95% Cl: 1.00 to 1.00) | **Pooled specificity Attended PSG:** 1.00 (95% Cl: 1.00 to 1.00) | **Accuracy (high risk):** 53% (95% Cl: 52 to 53%) **Accuracy (low risk):** 40% (95% Cl: 38 to 42%)

		Number of re					
Test result	Quality of the	Prevalen	ce 87%	Prevalence	Number of participants		
	Evidence (GRADE)	STOP- BANG Questionnaire	Attended PSG	STOP- BANG Questionnaire	Attended PSG	(studies)	
True positives (patients with OSA)		809 (783 to 827)	870 (870 to 870)	512 (495 to 523)	550 (550 to 550)		
	$\oplus \oplus \bigcirc \bigcirc$	61 fewer TP in STOP- BANG Questionnaire		38 fewer TP in STOP- BANG Questionnaire		4432 (10) ^{A-J}	
False negatives	LOW ^{1,2}	61 (43 to 87)	0 (0 to 0)	38 (27 to 55)	0 (0 to 0)	(10)	
(patients incorrectly classified as not having OSA)		61 more FN in STOP- BANG Questionnaire		38 more FN in STOP- BANG Questionnaire			
True negatives		47 (38 to 57)	130 (130 to 130)	162 (130 to 198)	450 (450 to 450)		
(patients without OSA)	$\Theta \Theta \bigcirc \bigcirc \bigcirc$		83 fewer TN in STOP- BANG Questionnaire		288 fewer TN in STOP- BANG Questionnaire		
False positives (patients incorrectly classified as having OSA)	LOW ^{1,2}	83 (73 to 92)	0 (0 to 0)	288 (252 to 320)	0 (0 to 0)	(10) ^{A-J}	
		83 more FP in STOP- BANG Questionnaire		288 more FP in S BANG Questionr			

²Wide confidence intervals for specificity

Figure S10—STOP-BANG Questionnaire vs. PSG to diagnose OSA in Suspected Adults (AHI \ge 15)

Study	ТР	FP	FN	TN	Sensitivity (95% CI)	Specificity (95% CI)	Sensitivity (95% CI)	Specificity (95% CI)
Alhouqani 2015	120	48	4	21	0.97 [0.92, 0.99]	0.30 [0.20, 0.43]	-	
BaHammam 2015	85	4	4	7	0.96 [0.89, 0.99]	0.64 [0.31, 0.89]	-	
Banhiran 2014	139	97	12	55	0.92 [0.87, 0.96]	0.36 [0.29, 0.44]	-	
Cowan 2014	56	58	0	15	1.00 [0.94, 1.00]	0.21 [0.12, 0.32]	-	-
Kim 2015	337	219	6	30	0.98 [0.96, 0.99]	0.12 [0.08, 0.17]	•	+
Ong 2010	148	97	14	63	0.91 [0.86, 0.95]	0.39 [0.32, 0.47]	+	-
Pataka 2014	1200	514	51	88	0.96 [0.95, 0.97]	0.15 [0.12, 0.18]	•	•
Pereira 2013	82	29	6	11	0.93 [0.86, 0.97]	0.28 [0.15, 0.44]		
Sadeghniiat-Haghighi 2015	306	185	12	100	0.96 [0.94, 0.98]	0.35 [0.30, 0.41]		

Pooled sensitivity: 0.95 [0.94, 0.97] Pooled specificity: 0.27 [0.20, 0.36] LR+: 1.31 [1.18, 1.45] LR-: 0.17 [0.12, 0.23] DOR: 7.86 [5.37, 11.49] Accuracy: 0.68 or <u>68%</u> Figure S11—STOP-BANG Questionnaire vs. PSG to diagnose OSA in Suspected Adults (AHI \ge 15)




Table S13—Summary of Findings table for STOP-BANG Questionnaire vs. PSG to diagnose OSA in Suspected Adults (AHI \ge 15)

References: Alouqani 2015 (A); BaHammam 2015 (B); Banhiran 2014 (C); Cowan 2014 (D); Kim 2015 (E); Ong 2010 (F); Pataka 2014 (G); Pereira 2013 (H); Sadeghniiat-Highighi 2015 (I)

Pooled sensitivity STOP-BANG Questionnaire: 0.95 (95% Cl: 0.94 to 0.97) | **Pooled specificity STOP-BANG Questionnaire:** 0.27 (95% Cl: 0.20 to 0.36) **Pooled sensitivity Attended PSG:** 1.00 (95% Cl: 1.00 to 1.00) | **Pooled specificity Attended PSG:** 1.00 (95% Cl: 1.00 to 1.00) | **Pooled specificity Attended PSG:** 1.00 (95% Cl: 1.00 to 1.00) | **Accuracy (high risk):** 70% (95% Cl: 69 to 72%) **Accuracy (low risk):** 43% (95% Cl: 42 to 44%)

		Number of re					
Test result	Quality of the	Prevalen	ce 64%	Prevalence	Number of participants		
	Evidence (GRADE)	STOP- BANG Questionnaire	Attended PSG	STOP- BANG Questionnaire	Attended PSG	(studies)	
True positives (patients with OSA)		614 (602 to 621)	640 (640 to 640)	240 (235 to 243)	250 (250 to 250)		
	$\oplus \oplus \bigcirc \bigcirc$		26 fewer TP in STOP- BANG Questionnaire		FOP- naire	4223 (9) ^{A-I}	
False negatives	LOW ^{1,2}	26 (19 to 38)	0 (0 to 0)	10 (7 to 15)	0 (0 to 0)	(9)	
(patients incorrectly classified as not having OSA)		26 more FN in STOP- BANG Questionnaire		10 more FN in STOP- BANG Questionnaire			
True negatives		90 (65 to 122)	360 (360 to 360)	188 (135 to 255)	750 (750 to 750)		
(patients without OSA)	$\Theta \oplus \bigcirc \bigcirc$		270 fewer TN in STOP- BANG Questionnaire		562 fewer TN in STOP- BANG Questionnaire		
False positives (patients incorrectly classified as having OSA)	LOW ^{1,2}	270 (238 to 295)	0 (0 to 0)	562 (495 to 615)	0 (0 to 0)	(9) ^{A-I}	
		270 more FP in STOP- BANG Questionnaire		562 more FP in S BANG Questionr			

²Wide confidence intervals for specificity

Figure S12—STOP-BANG Questionnaire vs. PSG to diagnose OSA in Suspected Adults (AHI \ge 30)

Study	TP	FP	FN	TN	Sensitivity (95% CI)	Specificity (95% CI)	Sensitivity (95% CI)	Specificity (95% CI)
Alhouqani 2015	85	83	2	23	0.98 [0.92, 1.00]	0.22 [0.14, 0.31]	-	
BaHammam 2015	45	9	18	28	0.71 [0.59, 0.82]	0.76 [0.59, 0.88]		
Banhiran 2014	94	142	3	64	0.97 [0.91, 0.99]	0.31 [0.25, 0.38]	-	-
Ong 2010	106	135	5	73	0.95 [0.90, 0.99]	0.35 [0.29, 0.42]	-	-
Pataka 2014	890	852	18	93	0.98 [0.97, 0.99]	0.10 [0.08, 0.12]	•	•
Pereira 2013	54	57	2	15	0.96 [0.88, 1.00]	0.21 [0.12, 0.32]		
Sadeghniiat-Haghighi 2015	189	278	13	123	0.94 [0.89, 0.97]	0.31 [0.26, 0.35]		

Pooled sensitivity: 0.94 [0.90, 0.97] Pooled specificity: 0.30 [0.17, 0.46] LR+: 1.34 [1.12, 1.61] LR-: 0.18 [0.14, 0.24] DOR: 7.37 [5.37, 10.1] Accuracy: 0.54 or <u>54%</u>

Figure S13—ROC Curve for STOP-BANG Questionnaire vs. PSG to diagnose OSA in Suspected Adults (AHI \ge 30)




Table S14—Summary of Findings table for STOP-BANG Questionnaire vs. PSG to diagnose OSA in Suspected Adults (AHI ≥ 30)

References: Alouqani 2015 (A); BaHammam 2015 (B); Banhiran 2014 (C); Ong 2010 (D); Pataka 2014 (E); Pereira 2013 (F); Sadeghniiat-Highighi 2015 (G)

 Pooled sensitivity STOP-BANG Questionnaire:
 0.94 (95% CI: 0.90 to 0.97) | Pooled specificity STOP-BANG Questionnaire:

 0.30 (95% CI: 0.17 to 0.46) Pooled sensitivity Attended PSG:
 1.00 (95% CI: 1.00 to 1.00) | Pooled specificity Attended PSG:

 1.00 (95% CI: 1.00 to 1.00) Accuracy (high risk):
 53% (95% CI: 53 to 55%) Accuracy (low risk):
 36% (95% CI: 33 to 40%)

		Number of re	(95% CI)			
Test result	Quality of the	Prevalen	ce 36%	Prevalence	Number of participants	
	Evidence (GRADE)	STOP- BANG Questionnaire	Attended PSG	STOP- BANG Questionnaire	Attended PSG	(studies)
True positives (patients with OSA)		338 (324 to 349)	360 (360 to 360)	94 (90 to 97)	100 (100 to 100)	
	$\oplus \oplus \bigcirc \bigcirc$	22 fewer TP in STOP- BANG Questionnaire		6 fewer TP in STOP-BANG Questionnaire		3449 (7) ^{A-G}
False negatives	LOW ^{1,2}	22 (11 to 36)	22 (11 to 36) 0 (0 to 0) 6 (3 to 10) 0 (0 to		0 (0 to 0)	(7)
(patients incorrectly classified as not having OSA)		22 more FN in STOP- BANG Questionnaire		6 more FN in STOP-BANG Questionnaire		
True negatives		192 (109 to 294)	640 (640 to 640)	270 (153 to 414)	900 (900 to 900)	
(patients without OSA)	$\oplus \oplus \bigcirc \bigcirc$		448 fewer TN in STOP- BANG Questionnaire		630 fewer TN in STOP- BANG Questionnaire	
False positives (patients incorrectly classified as having OSA)	LOW ^{1,2}	448 (346 to 531)	0 (0 to 0)	630 (486 to 747)	0 (0 to 0)	(7) ^{A-G}
		270 more FP in STOP- BANG Questionnaire		630 more FP in S BANG Questionn		

¹Broad range of specificity across studies ²Wide confidence intervals for specificity

Table S15—Summary of Findings table for STOP-BANG Questionnaire vs. HSAT to diagnose OSA in Suspected Adults (AHI \ge 5)

References: Chung 2013 (A)

Single study sensitivity STOP- BANG Questionnaire: 0.87 (95% CI: 0.80 to 0.92) | Single study specificity STOP- BANG Questionnaire: 0.33 (95% CI: 0.21 to 0.48) Single study sensitivity HSAT: 1.00 (95% CI: 1.00 to 1.00) | Single study specificity HSAT: 1.00 (95% CI: 1.00 to 1.00) Accuracy (high risk): 80% (95% CI: 72 to 86%) Accuracy (low risk): 63% (95% CI: 53 to 72%)

		Numbe	Number of results per 1000 patients tested (95% CI)						
Test result	Quality of the Evidence	Prevale	nce 87%	Prevale	Number of participants				
	(GRADE)	STOP- BANG Questionnaire	HSAT	STOP- BANG Questionnaire	HSAT	(studies)			
True positives		757 (696 to 800)	870 (870 to 870)	479 (440 to 506)	550 (550 to 550)				
OSA)	(patients with OSA) ⊕⊕⊕⊕		n STOP- BANG	71 fewer TP in S Questionnaire	71 fewer TP in STOP- BANG Questionnaire				
False negatives (patients	False negatives HIGH (patients	113 (174 to 70)	0 (0 to 0)	71 (44 to 110)	0 (0 to 0)	(1) ^A			
incorrectly classified as not having OSA)		113 more FN in Questionnaire	STOP- BANG	71 more FN in S ⁻ Questionnaire					
True negatives		43 (27 to 62)	130 (130 to 130)	149 (94 to 216)	450 (450 to 450)				
(patients without OSA)	⊕⊕⊕⊕	87 fewer TN in STOP- BANG Questionnaire		301 fewer TN in S Questionnaire	192				
False positives	HIGH	87 (68 to 103)	0 (0 to 0)	301 (234 to 356)	0 (0 to 0)	(1) ^A			
(patients incorrectly classified as having OSA)		87 more FP in S Questionnaire	STOP- BANG	301 more FP in S Questionnaire					

Table S16—Summary of Findings table for STOP-BANG Questionnaire vs. HSAT to diagnose OSA in Suspected Adults (AHI ≥ 15)

References: Chung 2013 (A); Nicholl 2013 (B)

Range of sensitivities STOP-BANG Questionnaire: 0.88 to 0.94 | Range of specificities STOP-BANG Questionnaire: 0.24 to 0.31

Range of sensitivities HSAT: 1.00 to 1.00 | Range of specificities HSAT: 1.00 to 1.00 Accuracy (high risk): 65% to 71% Accuracy (low risk): 40% to 47%

		Number	ed (95% CI)				
	Quality of the Evidence	Prevaler	nce 64%	Prevale	Number of participants		
	(GRADE)	STOP- BANG Questionnaire	HSAT	STOP- BANG Questionnaire	HSAT	(studies)	
True positives		563 to 602	640 to 640	220 to 235	250 to 250		
(patients with OSA)		38 to 77 fewer T BANG Question		15 to 30 fewer T BANG Question		004	
⊕ ⊕⊕ False negatives (patients incorrectly classified as not having OSA)	38 to 77	0 to 0	15 to 30	0 to 0	364 (2) ^{A,B}		
		38 to 77 more F BANG Questior		15 to 30 more FI Questionnaire			
True negatives		86 to 112	360 to 360	180 to 232	750 to 750		
(patients without OSA)		248 to 274 fewe BANG Question		570 to 518 fewer BANG Question			
False positives	$\bigoplus \bigoplus \bigoplus \bigcirc$ MODERATE ¹	248 to 274	0 to 0	518 to 570	0 to 0	364 (2) ^{A,B}	
(patients incorrectly classified as having OSA)		248 to 274 more BANG Question		518 to 570 more BANG Question			

Table S17—Summary of Findings table for STOP-BANG Questionnaire vs. HSAT to diagnose OSA in Suspected Adults (AHI ≥ 30)

References: Chung 2013 (A); Nicholl 2013 (B)

Range of sensitivities STOP- BANG Questionnaire: 0.88 to 1.00 | Range of specificities STOP- BANG Questionnaire: 0.20 to 0.53 Range of sensitivities HSAT: 1.00 to 1.00 | Range of specificities HSAT: 1.00 to 1.00 Accuracy (high risk): 44% to 70% Accuracy (low risk): 27% to 58%

		Number of	results per 10	000 patients test	ted (95% CI)	
Test result	Quality of the Evidence	Prevalenc	e 36%	Prevalence	Number of participants	
	(GRADE)	STOP- BANG Questionnaire	HSAT	STOP- BANG Questionnaire	HSAT	(studies)
True neoitivee		317 to 360	360 to 360	88 to 100	100 to 100	
True positives (patients with OSA)	$\oplus \oplus \bigcirc \bigcirc$	0 to 43 fewer TP in STOP- BANG Questionnaire		0 to 12 fewer T BANG Questic		364
False negatives	LOW ^{1,2}	0 to 43	0 to 0	0 to 12	0 to 0	(2) ^{A,B}
(patients incorrectly classified as not having OSA)		0 to 43 more FN in STOP- BANG Questionnaire		0 more to 12 fewer FN in STOP- BANG Questionnaire		
		128 to 339	640 to 640	180 to 477	900 to 900	
True negatives (patients without OSA)	$\Theta \Theta \bigcirc \bigcirc \bigcirc$	301 to 512 fewer TN in STOP- BANG Questionnaire		423 to 720 few STOP- BANG	364	
False positives (patients incorrectly classified as having OSA)	LOW ^{1,2}	301 to 512	0 to 0	423 to 720	0 to 0	(2) ^{A,B}
		301 to 512 more FP in STOP- BANG Questionnaire		423 to 720 mo BANG Questic		

¹Indirect evidence as one study consisted of pregnant women, and the other study consisted of chronic kidney disease and end-stage renal disease patients ²Braod range of specificity across studies

Table S18—Summary of Findings table for STOP-BANG Questionnaire vs. PSG or HSAT to diagnose OSA in Suspected Adults (AHI \geq 5)

References: Chung 2013 (A); Nicholl 2013 (B)

Range of sensitivities STOP- BANG Questionnaire: 0.18 to 0.90 | Range of specificities STOP- BANG Questionnaire: 0.28 to 0.88 Range of sensitivities PSG or HSAT: 1.00 to 1.00 | Range of specificities PSG or HSAT: 1.00 to 1.00 Accuracy (high risk): 19% to 90% Accuracy (low risk): 22% to 89%

	-	Number o	of results per 10	00 patients teste	d (95% CI)		
Test result	Quality of the Evidence	Prevaler	nce 87%	Prevale	Prevalence 55%		
	(GRADE)	STOP- BANG Questionnaire	PSG or HSAT	STOP- BANG Questionnaire	PSG or HSAT	_ participants (studies)	
True positives		157 to 783	870 to 870	99 to 495	550 to 550		
(patients with OSA)	, THE STATE OF THE	87 to 713 fewer BANG Question		55 to 451 fewer BANG Question	364 		
False negatives	LOW ^{1,2}	87 to 713	0 to 0	55 to 451	0 to 0	(2) ^{A,B}	
(patients incorrectly classified as not having OSA)		87 to 713 more BANG Question		55 to 451 more BANG Question			
True negatives		36 to 114	130 to 130	126 to 396	450 to 450		
(patients without OSA)	(patients without		N in STOP-	54 to 324 fewer BANG Question	364		
False positives	LOW ^{1,2}	16 to 94	0 to 0	54 to 324	0 to 0	(2) ^{A,B}	
(patients incorrectly classified as having OSA)		16 to 94 more F BANG Question		54 to 324 more BANG Questior			

¹Indirect evidence as one study consisted of pregnant women, and the other study consisted of chronic kidney disease and end-stage renal disease patients ²Broad range of specificity across studies

Table S19—Summary of Findings table for STOP-BANG Questionnaire vs. PSG or HSAT to diagnose OSA in Suspected Adults (AHI \ge 15)

References: Chung 2012 (A); Chung 2013 (B)

Range of sensitivities STOP- BANG Questionnaire: 0.10 to 0.95 | Range of specificities STOP- BANG Questionnaire: 0.11 to 0.88

Range of sensitivities PSG or HSAT: 1.00 to 1.00 | Range of specificities PSG or HSAT: 1.00 to 1.00 Accuracy (high risk): 10% to 92% Accuracy (low risk): 11% to 90%

		Number of results per 1000 patients tested (95% CI)					
Test result	Quality of the Evidence	Prevaler	nce 64%	Prevaler	Number of participants		
	(GRADE)	STOP- BANG Questionnaire	PSG or HSAT	STOP- BANG Questionnaire	PSG or HSAT	(studies)	
True positives		64 to 608	640 to 640	25 to 238	250 to 250		
(patients with OSA)		32 to 576 fewer TP in STOP- BANG Questionnaire		12 to 225 fewer 1 BANG Question			
False	⊕⊕⊖⊖ LOW ^{1,2}	32 to 576	0 to 0	12 to 225	0 to 0	1056 (2) ^{A,B}	
negatives (patients incorrectly classified as not having OSA)		32 to 576 more FN in STOP- BANG Questionnaire		12 to 225 more F BANG Question			
True negatives		40 to 317	360 to 360	83 to 660	750 to 750		
(patients without OSA)		43 to 320 fewer TN in STOP- BANG Questionnaire		90 to 667 fewer 1 BANG Question	1050		
False positives (patients incorrectly classified as having OSA)		43 to 320	0 to 0	90 to 667	0 to 0	- 1056 (2) ^{A,B}	
		43 to 320 more FP in STOP- BANG Questionnaire		90 to 667 more FP in STOP- BANG Questionnaire			

¹Indirect evidence as one study consisted of pregnant women ²Wide range of specificity and sensitivity

Table S20—Summary of Findings table for STOP-BANG Questionnaire vs. PSG or HSAT to diagnose OSA in Suspected Adults (AHI \ge 30)

References: Chung 2012 (A); Chung 2013 (B)

Range of sensitivities STOP- BANG Questionnaire: 0.28 to 1.00 | Range of specificities STOP- BANG Questionnaire: 0.17 to 0.88 Range of sensitivities PSG or HSAT: 1.00 to 1.00 | Range of specificities PSG or HSAT: 1.00 to 1.00 Accuracy (high risk): 21% to 92% Accuracy (low risk): 18% to 89%

		Numbe				
Test result	Quality of the Evidence	Prevalence 36%		Prevale	Number of participants	
	(GRADE)	STOP- BANG Questionnaire	PSG or HSAT	STOP- BANG Questionnaire	PSG or HSAT	(studies)
True positives		101 to 360	360 to 360	28 to 100	100 to 100	
(patients with OSA)		0 to 259 fewer TP in STOP- BANG Questionnaire		0 to 72 fewer TP in STOP-Bang Questionnaire		4050
False negatives	⊕⊕⊖⊖ LOW ^{1,2}	0 to 259	0 to 0	0 to 72	0 to 0	- 1056 (2) ^{A,B}
(patients incorrectly classified as not having OSA)		0 to 259 more FN in STOP- BANG Questionnaire		0 to 72 more FN Questionnaire		
True negatives		109 to 563	640 to 640	153 to 792	900 to 900	- 1056
(patients without OSA)		77 to 531 fewer TN in STOP- BANG Questionnaire		108 to 747 fewer TN in STOP- BANG Questionnaire		(2) ^{A,B}
False positives (patients incorrectly classified as having OSA)		77 to 531	0 to 0	108 to 747	0 to 0	
		77 to 531 more FP in STOP- BANG Questionnaire		108 to 747 more FP in STOP- BANG Questionnaire		

²Wide range of specificity and sensitivity

Figure S14—STOP Questionnaire vs. PSG to diagnose OSA in Suspected Adults (AHI ≥ 5)

Study	ТР	FP	FN	TN	Sensitivity (95% CI)	Specificity (95% CI)	Sensitivity (95% CI)	Specificity (95% CI)
Banhiran 2014	182	42	40	39	0.82 [0.76, 0.87]	0.48 [0.37, 0.60]	+	
Chung 2008	81	21	43	32	0.65 [0.56, 0.74]	0.60 [0.46, 0.74]		
Cowan 2014	94	27	3	5	0.97 [0.91, 0.99]	0.16 [0.05, 0.33]	-	
Luo 2014	170	9	27	6	0.86 [0.81, 0.91]	0.40 [0.16, 0.68]	-	
Pataka 2014	1427	296	74	56	0.95 [0.94, 0.96]	0.16 [0.12, 0.20]		

Pooled sensitivity: 0.88 [0.77, 0.94] Pooled specificity: 0.33 [0.18, 0.52] **LR+:** 1.31 [1.10, 1.57] **LR-:** 0.36 [0.27, 0.47] DOR: 3.68 [2.80, 4.83] Accuracy: 0.78 or 78%




Figure S15—ROC Curve for STOP Questionnaire vs. PSG to diagnose OSA in Suspected Adults (AHI \ge 5)

Table S21—Summary of Findings table for STOP Questionnaire vs. PSG to diagnose OSA in Suspected Adults (AHI \ge 5)

References: Chung 2008 (A); Cowan 2014 (B); Pataka 2014 (C); Luo 2014 (D); Banhiran 2014 (E)

Pooled sensitivity STOP Questionnaire: 0.88 (95% CI: 0.77 to 0.94) | **Pooled specificity STOP Questionnaire:** 0.33 (95% CI: 0.18 to 0.52) **Pooled sensitivity Attended PSG:** 1.00 (95% CI: 1.00 to 1.00) | **Pooled specificity Attended PSG:** 1.00 (95% CI: 1.00 to 1.00) **Accuracy (high risk):** 81% (95% CI: 74 to 86%) **Accuracy (low risk):** 63% (95% CI: 60 to 67%)

		Number of res					
Test result	Quality of the	Prevalen	Prevalence 87%		Prevalence 55%		
	Evidence (GRADE)	STOP Questionnaire	Attended PSG	STOP Questionnaire	Attended PSG	(studies)	
True positives		766 (670 to 818)	870 (870 to 870)	484 (424 to 517)	550 (550 to 550)		
(patients with OSA)	$\oplus \oplus \bigcirc \bigcirc$	104 fewer TP in STOP Questionnaire		66 fewer TP in STOP Questionnaire		2674	
False negatives (patients incorrectly classified as not having OSA)	LOW ^{1,2}	104 (52 to 200)	0 (0 to 0)	66 (33 to 126)	0 (0 to 0)	(5) ^{A-E}	
		104 more FN in STOP Questionnaire		66 more FN in STOP Questionnaire			
True negatives		43 (23 to 68)	130 (130 to 130)	149 (81 to 234)	450 (450 to 450)		
(patients without OSA)	⊕⊕⊖⊖ LOW ^{1,2}	87 fewer TN in STOP Questionnaire		301 fewer TN in STOP Questionnaire		2674	
False positives (patients incorrectly classified as having OSA)		87 (62 to 107)	0 (0 to 0)	301 (216 to 369)	0 (0 to 0)	(5) ^{A-E}	
		87 more FP in STOP Questionnaire		301 more FP in STOP Questionnaire			

²Wide confidence intervals for specificity

Table S22—Summary of Findings table for STOP Questionnaire vs. PSG to diagnose OSA in Suspected Adults (AHI \ge 15)

References: Chung 2008 (A); Pataka 2014 (B); Banhiran 2014 (C); Luo 2014 (D); Cowan (E)

Range of sensitivities STOP Questionnaire: 0.62 to 0.98 | Range of specificities STOP Questionnaire: 0.10 to 0.63 | Range of sensitivities Attended PSG: 1.00 to 1.00 | Accuracy (high risk): 60% to 79% | Accuracy (low risk): 45% to 48%

	Quality of the Evidence	Number	_			
Test result		Prevale	nce 64%	Prevale	Number of participants	
	(GRADE)	STOP Questionnaire	Attended PSG	STOP Questionnaire	Attended PSG	(studies)
True positives		397 to 627	640 to 640	155 to 245	250 to 250	
(patients with OSA)		13 to 243 fewer TP in STOP Questionnaire		5 to 95 fewer TP Questionnaire		
False negatives	⊕⊕⊕⊖ MODERATE ¹	13 to 243	0 to 0	5 to 95	0 to 0	2674 (5) ^{A-E}
(patients incorrectly classified as not having OSA)		13 to 243 more FN Questionnaire	N in STOP	5 to 95 more FN Questionnaire		
True negatives		36 to 227	360 to 360	75 to 473	750 to 750	
(patients without OSA)		133 to 324 fewer TN in STOP Questionnaire		277 to 675 fewer Questionnaire		
False positives	⊕⊕⊕⊖ MODERATE ¹	103 to 324	0 to 0	277 to 675	0 to 0	2674 (5) ^{A-E}
(patients incorrectly classified as having OSA)		133 to 324 more FP in STOP Questionnaire		277 to 675 more Questionnaire		
¹ Wide range of val	ues for sensitivit	y and specificity				

Table S23—Summary of Findings table for STOP Questionnaire vs. PSG to diagnose OSA in Suspected Adults (AHI \ge 30)

References: Pataka 2014 (A); Banhiran 2014 (B); Luo 2014 (C)

Range of sensitivities STOP Questionnaire: 0.91 to 0.97 | Range of specificities STOP Questionnaire: 0.11 to 0.36 | Range of sensitivities Attended PSG: 1.00 to 1.00 | Accuracy (high risk): 48% to 49% | Accuracy (low risk): 25% to 34%

	Quality of the	Number					
Test result		Prevale	nce 36%	Prevale	Number of participants		
	(GRADE)	STOP Questionnaire	Attended PSG	STOP Questionnaire	Attended PSG	(studies)	
True positives		328 to 349	360 to 360	91 to 97	100 to 100		
(patients with OSA)		11 to 32 fewer TP in STOP Questionnaire		3 to 9 fewer TP i Questionnaire	n STOP		
False negatives	$\bigoplus \bigoplus \bigoplus \bigcirc \bigcirc$ MODERATE ¹	11 to 32	0 to 0	3 to 9	0 to 0	2368 (3) ^{A-C}	
(patients incorrectly classified as not having OSA)		11 to 32 more FN Questionnaire	in STOP	3 to 9 more FN in Questionnaire			
True negatives		70 to 230	640 to 640	99 to 324	900 to 900		
(patients without OSA)		410 to 570 fewer TN in STOP Questionnaire		576 to 801 fewer Questionnaire			
False positives	$\bigoplus \bigoplus \bigoplus \bigcirc \bigcirc$ MODERATE ¹	410 to 570	0 to 0	576 to 801	0 to 0	2368 (3) ^{A-C}	
(patients incorrectly classified as having OSA)		410 to 570 more FP in STOP Questionnaire		576 to 801 more Questionnaire			
¹ Wide range of val	ues for specificit	у		·			

Table S24—Summary of Findings table for Morphometric Model vs. PSG to diagnose OSA in Suspected Adults (AHI \ge 5)

References: Gurubhagavatula 2013 (A); Kushida 1997 (B)

Range of sensitivities Morphometric Model: 0.88 to 0.98 | Range of specificities Morphometric Model: 0.11 to 0.31 Range of sensitivities Attended PSG: 1.00 to 1.00 | Range of specificities Attended PSG: 1.00 to 1.00

Test result	Quality of the Evidence	Numbe				
		Preval	ence 87%	Prevale	Number of participants	
	(GRADE)	Morphometric Model	Attended PSG	Morphometric Model	Attended PSG	(studies)
True positives		766 to 853	870 to 870	484 to 539	550 to 550	
(patients with OSA)		17 to 104 fewer TP in Morphometric Model		11 to 66 fewer T Morphometric M		
False negatives	⊕⊕⊕() MODERATE ¹	17 to 104	0 to 0	11 to 66	0 to 0	- 350 (2) ^{A,B}
(patients incorrectly classified as not having OSA)		17 to 104 more FN in Morphometric Model		11 to 66 more FN Morphometric M		
True negatives		14 to 40	130 to 130	49 to 139	450 to 450	
(patients without OSA)		90 to 116 fewer TN in Morphometric Model		311 to 401 fewer Morphometric M	050	
False positives	$\bigoplus \bigoplus \bigoplus \bigcirc$ MODERATE ¹	90 to 116	0 to 0	311 to 401	0 to 0	- 350 (2) ^{A,B}
(patients incorrectly classified as having OSA)		90 to 116 more FP in Morphometric Model		311 to 401 more Morphometric M		
¹ Wide range of value	ues for specificity					

Table S25—Summary of Findings table for Adjusted Neck Circumference vs. HSAT to diagnose OSA in Suspected Adults (AHI \ge 15)

References: Nicholl 2013 (A)

Range of sensitivities Adjusted Neck Circumference: 0.34 to 0.93 | Range of specificities Adjusted Neck Circumference: 0.37 to 0.94 Range of sensitivities HSAT: 1.00 to 1.00 | Range of specificities HSAT: 1.00 to 1.00 Accuracy (high risk): 35% to 93% Accuracy (low risk): 36% to 94%

Test result	Ouglity of	Numbe				
	Quality of the	Prevale	ence 64%	Prevale	Number of participants	
	Evidence (GRADE)	Adjusted Neck Circumference	HSAT	Adjusted Neck Circumference	HSAT	(studies)
True positives		218 to 595	640 to 640	85 to 233	250 to 250	
(patients with OSA)		45 to 422 fewer TP in Adjusted Neck Circumference		17 to 165 fewer TP in Adjusted Neck Circumference		
False negatives	⊕⊕⊕() MODERATE ¹	45 to 422	0 to 0	17 to 165	0 to 0	— 172 (1) ^A
(patients incorrectly classified as not having OSA)		45 to 422 more FN in Adjusted Neck Circumference		17 to 165 more F Neck Circumfere		
True negatives		133 to 338	360 to 360	277 to 705	750 to 750	
(patients without OSA)	$\oplus \oplus \oplus \bigcirc$ MODERATE ¹	22 to 227 fewer TN in Adjusted Neck Circumference		45 to 473 fewer T Neck Circumfere		
False positives		22 to 227	0 to 0	45 to 473	0 to 0	— 172 (1) ^A
(patients incorrectly classified as having OSA)		22 to 227 more FP in Adjusted Neck Circumference		45 to 473 more FP in Adjusted Neck Circumference		
¹ Wide range of val	ues for specificity	and sensitivity				

Table S26—Summary of Findings table for Adjusted Neck Circumference vs. HSAT to diagnose OSA in Suspected Adults (AHI ≥ 30)

References: Nicholl 2013 (A); Gurubhagavatula 2013 (B)

Range of sensitivities Adjusted Neck Circumference: 0.40 to 0.96 | Range of specificities Adjusted Neck Circumference: 0.32 to 0.92 Range of sensitivities HSAT: 1.00 to 1.00 | Range of specificities HSAT: 1.00 to 1.00 Accuracy (high risk): 35% to 94% Accuracy (low risk): 33% to 92%

	-	Number					
Test result	Quality of the Evidence	Prevalence 36%		Prevaler	Number of participants		
	(GRADE)	Adjusted Neck Circumference	HSAT	Adjusted Neck Circumference	HSAT	(studies)	
True positives		144 to 346	360 to 360	40 to 96	100 to 100		
(patients with OSA)		14 to 216 fewer TP in Adjusted Neck Circumference		4 to 60 fewer TP i Circumference	n Adjusted Neck		
False negatives	⊕⊕⊕⊖ MODERATE ^{1,2}	14 to 216	0 to 0	4 to 60	0 to 0	422 (2) ^{A,B}	
(patients incorrectly classified as not having OSA)		14 to 216 more FN in Adjusted Neck Circumference		4 to 60 more FN i Circumference			
True negatives		205 to 589	640 to 640	288 to 828	900 to 900		
(patients without OSA)	$\oplus \oplus \oplus \bigcirc$ MODERATE ¹	51 to 435 fewer TN in Adjusted Neck Circumference		72 to 612 fewer T Neck Circumferer	100		
False positives		51 to 435	0 to 0	72 to 612	0 to 0	422 (2) ^{A,B}	
(patients incorrectly classified as having OSA)		51 to 435 more FP in Adjusted Neck Circumference		72 to 612 more FP in Adjusted Neck Circumference			
¹ Wide range of val	ues for specificity	and sensitivity					

Table S27—Summary of Findings table for Multivariable Apnea Prediction (MAP) vs. PSG to diagnose OSA in Suspected Adults (AHI \ge 5)

References: Gurubhagavatula 2001 (A); Gurubhagavatula 2013 (B); Rofail 2010 (C); Wilson 2014 (D)

Range of sensitivities MAP: 0.68 to 0.85 | Range of specificities MAP: 0.56 to 0.92 Range of sensitivities Attended PSG: 1.00 to 1.00 | Range of specificities Attended PSG: 1.00 to 1.00 Accuracy (high risk): 66% to 81% Accuracy (low risk): 63% to 79%

Test result	Quality of the Evidence	Numl	Number of			
		Prevalence 87%		Prev	Prevalence 55%	
	(GRADE)	MAP	Attended PSG	MAP	Attended PSG	(studies)
True positives		592 to 739	870 to 870	374 to 468	550 to 550	
(patients with OSA)		131 to 278 fewer TP in MAP		82 to 176 fewe	er TP in MAP	
False negatives (patients incorrectly classified as not having OSA) ⊕⊕⊕○ MODERATE ¹	131 to 278	0 to 0	82 to 170	0 to 0	683 (4) ^{A-D}	
	MODERATE	131 to 278 more FN in MAP		82 to 176 more FN in MAP		
True negatives		73 to 120	130 to 130	252 to 414	450 to 450	
(patients without OSA)		10 to 57 fewer TN in MAP		36 to 198 fewe	36 to 198 fewer TN in MAP	
False positives	$\oplus \oplus \oplus \bigcirc$ MODERATE ¹	10 to 57	0 to 0	36 to 198	0 to 0	683 (4) ^{A-D}
(patients norrectly classified as having OSA)	MODEIXIL	10 to 57 more FP in MAP		36 to 198 more FP in MAP		- ()

Table S28—MAP vs. PSG to diagnose OSA in Suspected Adults (AHI ≥ 30)

References: Gurubhagavatula 2001 (A); Gurubhagavatula 2013 (B); Morales 2012 (C); Wilson 2014 (D)

Range of sensitivities MAP: 0.80 to 0.90 | Range of specificities MAP: 0.44 to 0.72 Range of sensitivities Attended PSG: 1.00 to 1.00 | Range of specificities Attended PSG: 1.00 to 1.00 Accuracy (high risk): 58% to 70% Accuracy (low risk): 50% to 50%

	Quality of the	Numbe	Number of			
Test result	Evidence	Prevalence 36%		Prevalence 10%		participants
	(GRADE)	MAP	Attended PSG	MAP	Attended PSG	(studies)
True positives	288 to 360	360 to 360	80 to 100	100 to 100		
(patients with OSA)			0 to 72 fewer TP in MAP		TP in MAP	
Talse negatives	$\oplus \oplus \oplus \bigcirc$ MODERATE ¹	0 to 72	0 to 0	0 to 20	0 to 0	436 (4) ^{A-D}
(patients incorrectly classified as not having OSA)	classified as not	36 to 72 more FN in MAP		0 to 20 more FN in MAP		- ()
True negatives		122 to 461	640 to 640	171 to 648	900 to 900	
(patients without OSA)		179 to 518 fewer TN in MAP		252 to 729 fewer TN in MAP		
False positives	$\oplus \oplus \oplus \bigcirc$ MODERATE ¹	179 to 518	0 to 0	252 to 729	0 to 0	436 (4) ^{A-D}
(patients incorrectly classified as having OSA)	MODERATE	179 to 518 more FP in MAP		252 to 729 more FP in MAP		- ()
¹ Wide range of value	ues for specificity					

Table S29—Summary of Findings table for Prediction Models vs. PSG to diagnose OSA in Suspected Adults (AHI \ge 5)

References: Chang 2014 (A); Zou 2013 (B)

Range of sensitivities Prediction Models: 0.33 to 0.90 | Range of specificities Prediction Models: 0.50 to 1.00 Range of sensitivities Attended PSG: 1.00 to 1.00 | Range of specificities Attended PSG: 1.00 to 1.00 Accuracy (high risk): 58% to 80% Accuracy (low risk): 61% to 88%

	Quality of the Evidence	Number	(95% CI)			
Test result		Prevalence 87%		Prevalence 55%		Number of participants
	(GRADE)	Prediction Models	Attended PSG	Prediction Models	Attended PSG	(studies)
True positives		287 to 783	870 to 870	182 to 495	550 to 550	
(patients with OSA)	(patients with DSA)		87 to 583 fewer TP in Prediction Models		55 to 368 fewer TP in Prediction Models	
False negatives	⊕⊕⊕⊖ MODERATE ¹	87 to 583	0 to 0	55 to 368	0 to 0	- 1089 (2) ^{A,B}
(patients incorrectly classified as not having OSA)		87 to 583 more FN in Prediction Models		55 to 368 more FN in Prediction Models		
True negatives		65 to 130	130 to 130	225 to 450	450 to 450	
(patients without OSA)	(patients without OSA)		0 to 65 fewer TN in Prediction Models		0 to 225 fewer TN in Prediction Models	
False positives	$\bigoplus \bigoplus \bigoplus \bigcirc$ MODERATE ¹	0 to 65	0 to 0	0 to 225	0 to 0	- 1089 (2) ^{A,B}
(patients incorrectly classified as having OSA)		0 to 65 more FP in Prediction Models		0 to 225 more FP in Prediction Models		
¹ Wide values of se	nsitivity and specif	icity				

Table S30—Summary of Findings table for Prediction Models vs. PSG to diagnose OSA in Suspected Adults (AHI \ge 15)

References: Sharma 2006 (A); Zerah-Lancner 2000 (B)

Range of sensitivities Prediction Models: 0.82 to 1.00 | Range of specificities Prediction Models: 0.84 to 0.91 Range of sensitivities Attended PSG: 1.00 to 1.00 | Range of specificities Attended PSG: 1.00 to 1.00 Accuracy (high risk): 85% to 96% Accuracy (low risk): 85% to 92%

		Number	-			
Test result	Quality of the Evidence (GRADE)	Prevalence 64%		Prevalence 25%		Number of participants
		Prediction Models	Attended PSG	Prediction Models	Attended PSG	(studies)
True positives		525 to 640	640 to 640	205 to 250	250 to 250	
(patients with OSA)		0 to 115 fewer TP in Prediction Models		0 to 45 fewer TP in Prediction Models		
False negatives	⊕⊕⊕ HIGH	0 to 115	0 to 0	0 to 45	0 to 0	287 (2) ^{A,B}
(patients incorrectly classified as not having OSA)		0 to 115 more FN in Prediction Models		0 to 45 more FN in Prediction Models		
True negatives		302 to 328	360 to 360	630 to 683	750 to 750	
(patients without OSA)	atients without SA)		32 to 58 fewer TN in Prediction Models		67 to 120 fewer TN in Prediction Models	
False positives	⊕⊕⊕⊕ HIGH	32 to 58	0 to 0	67 to 120	0 to 0	- 287 (2) ^{A,B}
(patients incorrectly classified as having OSA)		32 to 58 more FP in Prediction Models		67 to 120 more FP in Prediction Models		

Table S31—Summary of Findings table for Prediction Models vs. HSAT to diagnose OSA in Suspected Adults (AHI \ge 30)

References: Platt 2013 (A); Morales 2012 (B); Kolotkin 2011 (C)

Range of sensitivities Prediction Models: 0.76 to 0.97 | Range of specificities Prediction Models: 0.19 to 0.75 Range of sensitivities Attended PSG: 1.00 to 1.00 | Range of specificities Attended PSG: 1.00 to 1.00 Accuracy (high risk): 58% to 70% Accuracy (low risk): 51% to 52%

	Prevalence Prediction Models 274 to 349 11 to 86 fewer TP Models	HSAT 360 to 360	Prevale Prediction Models 76 to 97	HSAT	Number of participant s (studies)
₽⊕○	274 to 349 11 to 86 fewer TP	360 to 360	Models	т	-
	11 to 86 fewer TP		76 to 97	100 to 100	
		in Prediction			
	11 to 86 fewer TP in Prediction Models		3 to 24 fewer TP in Prediction Models		
$\bigoplus \bigoplus \bigoplus \bigcirc$ MODERATE ¹	11 to 86	0 to 0	3 to 24	0 to 0	697 (3) ^{A-C}
	11 to 86 more FN in Prediction Models		3 to 24 more FN in Prediction Models		
	122 to 480	640 to 640	171 to 675	900 to 900	
	160 to 518 fewer TN in Prediction Models		225 to 729 fewer TN in Prediction Models		
	160 to 518	0 to 0	225 to 729	0 to 0	697 (3) ^{A-C}
	160 to 518 more FP in Prediction Models		225 to 729 more FP in Prediction Models		
	⊕⊖ ERATE ¹	⊕	 ⊕ ERATE¹ 160 to 518 0 to 0 160 to 518 more FP in Prediction 	Image: Constraint of the second sec	Image: Construction Image: Construction <thimage: construction<="" th=""> Image: Construction</thimage:>

Table S32—Summary of Findings table for OSA 50 vs. PSG to diagnose OSA in Suspected Adults (AHI \ge 15)

References: Firat 2012 (A)

 $\begin{array}{l} \textbf{Single study sensitivity OSA 50: } 0.63 \ (95\% \ Cl: \ 0.49 \ to \ 0.77) \ | \ \textbf{Single study specificity OSA 50: } 0.82 \ (95\% \ Cl: \ 0.70 \ to \ 0.94) \\ \textbf{Single study sensitivity Attended PSG: } 1.00 \ (95\% \ Cl: \ 1.00 \ to \ 1.00) \ | \ \textbf{Single study specificity Attended PSG: } 1.00 \ (95\% \ Cl: \ 0.70 \ to \ 0.95\% \ Cl: \ 0.70 \ to \ 0.95\% \ Cl: \ 0.70 \ to \ 0.70) \\ \textbf{Cl: } 1.00 \ to \ 1.00) \ \textbf{Accuracy (low risk): } 77\% \ (95\% \ Cl: \ 65 \ to \ 90\%) \\ \end{array}$

	Quality of the	Number	Number of			
Test result	Evidence	Prevalence 64%		Prevalence 25%		participants
	(GRADE)	OSA 50	Attended PSG	OSA 50	Attended PSG	(studies)
True positives		403 (314 to 493)	640 (640 to 640)	158 (123 to 193)	250 (250 to 250)	
(patients with OSA)	⊕⊕⊖⊖ LOW ^{1,2}	237 fewer TP in OSA 50		92 fewer TP in OSA 50		85
False negatives (patients incorrectly		237 (147 to 326)	0 (0 to 0)	92 (57 to1 27)	0 (0 to 0)	(1) ^A
classified as not having OSA)		237 more FN in OSA 50		92 more FN in OSA 50		
True negatives (patients without		295 (252 to 338)	360 (360 to 360)	615 (525 to 705)	750 (750 to 750)	
ÖSA)	$\oplus \oplus \bigcirc \bigcirc$	65 fewer TN in	OSA 50	135 fewer TN in OSA 50		85
False positives	LOW ^{1,2}	65 (22 to 108)	0 (0 to 0)	135 (45 to 225)	0 (0 to 0)	(1) ^A
(patients incorrectly classified as having OSA)		65 more FP in OSA 50		135 more FP in OSA 50		

²Wide confidence intervals for sensitivity and specificity

Table S33—Summary of Findings table for OSA 50 vs. HSAT to diagnose OSA in Suspected Adults (AHI \ge 30)

References: Chai-Coetzer 2011 (A)

Single study sensitivity OSA 50: 0.88 (95% CI: 0.60 to 0.98) | Single study specificity OSA 50: 0.82 (95% CI: 0.70 to 0.90) Single study sensitivity HSAT: 1.00 (95% CI: 1.00 to 1.00) | Single study specificity HSAT: 1.00 (95% CI: 1.00 to 1.00) Accuracy (high risk): 84% (95% CI: 66 to 93%) Accuracy (low risk):83% (95% CI: 69 to 91%)

	Quality of the	Number	(95% CI)	Number of		
Test result	Evidence	Prevalence 36%		Prevalence 10%		participants (studies)
	(GRADE)	OSA 50	HSAT	OSA 50	HSAT	(studies)
True positives		317 (216 to 353)	360 (360 to 360)	88 (60 to 98)	100 (100 to 100)	
(patients with OSA)	⊕⊕⊕⊖ MODERATE ¹	43 fewer TP in OSA 50		12 fewer TP in OSA 50		78
False negatives		43 (7 to144)	0 (0 to 0)	12 (2 to 40)	0 (0 to 0)	(1) ^A
(patients incorrectly classified as not having OSA)		43 more FN in OSA 50		12 more FN in OSA 50		
True negatives (patients without	⊕⊕⊕⊖	525 (448 to 576)	640 (640 to 640)	738 (630 to 810)	900 (900 to 900)	
ÔSA)		115 fewer TN in 0	OSA 50	162 fewer TN in OSA 50		78
False positives	MODERATE ¹	115 (64 to192)	0 (0 to 0)	162 (90 to 270)	0 (0 to 0)	(1) ^A
(patients incorrectly classified as having OSA)		115 more FP in OSA 50		162 more FP in (DSA 50	
¹ Wide confidence inte	rvals for sensitivi	ty and specificity		•		

Table S34—Summary of Findings table for Clinical Decision Support System vs. PSG to diagnose OSA in Suspected Adults (AHI ≥ 5)

References: LaPorta 2012 (A)

Single study sensitivity Clinical Decision Support System: 0.98 (95% CI: 0.92 to 1.00) | Single study specificity Clinical Decision Support System: 0.87 (95% CI: 0.66 to 0.97) Single study sensitivity Attended PSG: 1.00 (95% CI: 1.00 to 1.00) | Single study specificity Attended PSG: 1.00 (95% CI: 1.00 to 1.00) Accuracy (high risk): 97% (95% CI: 89 to 100%) Accuracy (low risk): 93% (95% CI: 80 to 99%)

		Number				
Test result	Quality of the Evidence	Prevalence 87%		Prevale	Number of participants	
	(GRADE)	Clinical Decision Support System	Attended PSG	Clinical Decision Support System	Attended PSG	(studies)
True positives	⊕⊕⊖⊖ LOW ^{1,2}	853 (800 to 870)	870 (870 to 870)	539 (506 to 550)	550 (550 to 550)	
(patients with OSA)		17 fewer TP in Clinical Decision Support System		11 fewer TP in Clinical Decision Support System		91
False negatives		17 (0 to 70)	0 (0 to 0)	11 (0 to44)	0 (0 to 0)	(1) ^A
(patients incorrectly classified as not having OSA)		17 more FN in Clinical Decision Support System		11 more FN in Clinical Decision Support System		
True negatives		113 (86 to 126)	130 (130 to 130)	391 (297 to 436)	450 (450 to 450)	
(patients without OSA)	⊕⊕⊖⊖ LOW ^{1,2}	17 fewer TN in Clinical Decision Support System		59 fewer TN in Clinical Decision Support System		91
False positives (patients incorrectly classified as having OSA)		17 (4 to 44)	0 (0 to 0)	59 (14 to 153)	0 (0 to 0)	(1) ^A
		17 more FP in Clinical Decision Support System		59 more FP in Clinical Decision Support System		

Indirect evidence as study only included patients with ischemic heart disease

²Wide confidence intervals for specificity

Table S35—Summary of Findings table for (Obstructive Sleep Apnea Hypopnea Syndrome) OSAHS Score vs. PSG to diagnose OSA in Suspected Adults (AHI \ge 5)

References: Friedman 2010 (A)

Single study sensitivity OSAHS Score: 0.86 (95% CI: 0.80 to 0.91) | Single study specificity OSAHS Score: 0.47 (95% CI: 0.34 to 0.56) |Single study sensitivity Attended PSG: 1.00 (95% CI: 1.00 to 1.00) | Single study specificity Attended PSG: 1.00 (95% CI: 1.00 to 1.00) Accuracy (high risk): 81% (95% CI: 74 to 86%) Accuracy (low risk): 68% (95% CI: 59 to 75%)

	Quality of the	Number	Number of results per 1000 patients tested (95% CI)				
Test result	Evidence	Prevalence 87%		Prevalence 55%		Number of participants	
	(GRADE)	OSAHS Score	Attended PSG	OSAHS Score	Attended PSG	 (studies) 	
True positives (patients with		748 (696 to 792)	870 (870 to 870)	473 (440 to 501)	550 (550 to 550)		
ÖSA)		122 fewer TP in OSAHS Score		77 fewer TP in O	SAHS Score	222	
False negatives $\bigoplus \bigoplus \bigoplus \bigcirc$ MODERATE1	122 (78 to174)	0 (0 to 0)	77 (49 to110)	0 (0 to 0)	223 (1) ^A		
(patients incorrectly classified as not having OSA)		122 more FN in OSAHS Score		77 more FN in OSAHS Score			
True negatives (patients without		61 (44 to 73)	130 (130 to 130)	211 (153 to 252)	450 (450 to 450)		
ÖSA)		69 fewer TN in OSAHS Score		239 fewer TN in OSAHS Score			
False positives	$\oplus \oplus \oplus \bigcirc$ MODERATE ¹	69 (57 to 86)	0 (0 to 0)	239 (198 to 297)	0 (0 to 0)	- 223 (1) ^A	
(patients incorrectly classified as having OSA)		69 more FP in OSAHS Score		239 more FP in OSAHS Score			
¹ Wide confidence in	ntervals for specific	city					

Table S36—Summary of Findings table for Kushida Index vs. PSG to diagnose OSA in Suspected Adults (AHI \ge 5)

References: Kushida 1997 (A)

Single study sensitivity Kushida Index: 0.98 (95% CI: 0.95 to 0.99) | Single study specificity Kushida Index: 1.00 (95% CI: 0.92 to 1.00) | Single study sensitivity Attended PSG: 1.00 (95% CI: 1.00 to 1.00) | Single study specificity Attended PSG: 1.00 (95% CI: 1.00 to 1.00) | Single study specificity Attended PSG: 1.00 (95% CI: 1.00 to 1.00) | Single study specificity Attended PSG: 1.00 (95% CI: 1.00 to 1.00) | Single study specificity Attended PSG: 1.00 (95% CI: 95% CI: 95% CI: 95% CI: 95% CI: 99%) | Single study specificity Attended PSG: 1.00 (95% CI: 95% C

	Quality of the Evidence	Number	Number of			
Test result		Prevalence 87%		Prevalence 55%		participants
	(GRADE)	Kushida Index	Attended PSG	Kushida Index	Attended PSG	(studies)
True positives		853 (827 to 861)	870 (870 to 870)	539 (523 to 545)	550 (550 to 550)	
(patients with OSA)	⊕⊕⊕⊕ HIGH	17 fewer TP in Kushida Index		11 fewer TP in Kushida Index		301
False negatives		17 (9 to43)	0 (0 to 0)	11 (5 to 27)	0 (0 to 0)	(1) ^A
(patients incorrectly classified as not having OSA)		17 more FN in Kushida Index		11 more FN in Kushida Index		
True negatives (patients without		130 (120 to 130)	130 (130 to 130)	450 (414 to 450)	450 (450 to 450)	
ÔSA)	$\oplus \oplus \oplus \oplus$	0 fewer TN in Ku	shida Index	0 fewer TN in Kushida Index		301
False positives	HIGH	0 (0 to10)	0 (0 to 0)	0 (0 to 36)	0 (0 to 0)	(1) A
(patients incorrectly classified as having OSA)		0 fewer FP in Kushida Index		0 fewer FP in Kushida Index		

Home sleep apnea testing for the diagnosis of obstructive sleep apnea in adults

Table S37—Summary of Findings table for Type 2 HSAT vs. PSG to diagnose OSA in Suspected Adults (AHI \ge 5)

References: Campbell 2011 (A); Banhiran 2014 (B)

Range of sensitivities Type 2 HSAT: 0.88 to 0.97 | Range of specificities Type 2 HSAT: 0.50 to 0.56 Range of sensitivities Attended: 1.00 to 1.00 | Range of specificities Attended: 1.00 to 1.00 Accuracy (high risk): 84% to 91% Accuracy (low risk): 73% to 77%

Test result	Quality of the	Number	Number of			
	Evidence	Prevalence 87%		Prevalence 55%		participants
	(GRADE)	Type 2 HSAT	Attended	Type 2 HSAT	Attended	(studies)
Truce in a sidiur a		766 to 844	870 to 870	484 to 534	550 to 550	
True positives (patients with OSA)	$\oplus \oplus \oplus \oplus$	26 to 104 fewer TP in Type 2 HSAT		16 to 66 fewer TP in Type 2 HSAT		116
False negatives	HIGH	26 to 104	0 to 0	16 to 66	0 to 0	116 (2) (2)
(patients incorrectly classified as not having OSA)		26 to 104 more FN in Type 2 HSAT		16 to 66 more FN in Type 2 HSAT		
True negatives		65 to 73	130 to 130	225 to 252	450 to 450	
(patients without OSA)	atients without		57 to 65 fewer TN in Type 2 HSAT		198 to 225 fewer TN in Type 2 HSAT	
False positives (patients incorrectly classified as having OSA)	HIGH	57 to 65	0 to 0	198 to 225	0 to 0	(2) ^{A,B}
		57 to 65 more FP in Type 2 HSAT		198 to 225 more FP in Type 2 HSAT		

Table S38—Summary of Findings table for Type 2 HSAT vs. PSG to diagnose OSA in Suspected Adults (AHI \ge 15)

References: Campbell 2011 (A); Banhiran 2014 (B)

Range of sensitivities Type 2 HSAT: 0.94 to 0.95 | Range of specificities Type 2 HSAT: 0.76 to 0.77 Range of sensitivities Attended: 1.00 to 1.00 | Range of specificities Attended: 1.00 to 1.00 Accuracy (high risk): 88% to 88% Accuracy (low risk): 81% to 81%

Test result	Quality of the	Number	(95% CI)	Number of participants		
	Evidence	Prevalence 64%			Prevalence 25%	
	(GRADE)	Type 2 HSAT	Attended	Type 2 HSAT	Attended	(studies)
True positives		602 to 608	640 to 640	235 to 238	250 to 250	
True positives (patients with OSA)	$\oplus \oplus \oplus \oplus$	32 to 38 fewer TP in Type 2 HSAT		12 to 15 fewer TP in Type 2 HSAT		116
False negatives	HIGH	32 to 38	0 to 0	12 to 15	0 to 0	(2) ^{A,B}
(patients incorrectly classified as not having OSA)		32 to 38 more FN in Type 2 HSAT		12 to 15 more FN in Type 2 HSAT		
True negatives		274 to 277	360 to 360	570 to 578	250 to 250	
(patients without OSA)	$\oplus \oplus \oplus \oplus$	83 to 86 fewer TN in Type 2 HSAT		172 to 180 fewer TN in Type 2 HSAT		116
False positives (patients incorrectly classified as having OSA)	HIGH	83 to 86	0 to 0	172 to 180	0 to 0	(2) ^{A,B}
		83 to 86 more FP in Type 2 HSAT		172 to 180 more FP in Type 2 HSAT		

Table S39—Summary of Findings table for Type 3 HSAT vs. PSG to diagnose OSA in Suspected Adults (AHI \ge 5)

References: Gjevre 2011 (A); Masa 2011 Thorax (B); Polese 2012 (C); Santos-Silva 2009 (D); Yin 2006 (E); Planes 2010 (F); Masa 2013 (G)

Range of sensitivities Type 3 HSAT: 0.90 to 1 | Range of specificities Type 3 HSAT: 0.30 to 0.67 Range of sensitivities Attended: 1.00 to 1.00 | Range of specificities Attended: 1.00 to 1.00 Accuracy (high risk): 84% to 91% Accuracy (low risk): 70% to 78%

	Quality of the	Number	(95% CI)	Number of		
Test result	Evidence	Prevale	nce 87%	Prevale	participants	
	(GRADE)	Type 3 HSAT	Attended	Type 3 HSAT	Attended	(studies)
True positives		783 to 870	870 to 870	495 to 550	550 to 550	
(patients with OSA)		0 to 87 fewer TP	in Type 3 HSAT	0 to 55 fewer TP	in Type 3 HSAT	1001
False negatives	$\oplus \oplus \oplus \bigcirc$ MODERATE ¹	0 to 87	0 to 0	0 to 55	0 to 0	1001 (7) ^{A-G}
(patients incorrectly classified as not having OSA)		0 to 87 more FN	in Type 3 HSAT	0 to 55 more FN		
True negatives		39 to 87	130 to 130	135 to 302	450 to 450	
(patients without OSA)	⊕⊕⊕⊖	43 to 91 fewer TN in Type 3 HSAT		148 to 315 fewer HSAT	1001	
False positives	MODERATE ¹	43 to 91	0 to 0	180 to 315	0 to 0	(7) ^{A-G}
(patients incorrectly classified as having OSA)		43 to 91 more FP in Type 3 HSAT		148 to 315 more FP in Type 3 HSAT		
¹ Wide range of values	for specificity					

Table S40—Summary of Findings table for Type 3 HSAT vs. PSG to diagnose OSA in Suspected Adults (AHI \ge 15)

References: Garcia-Diaz 2007 (A); Gjevre 2011 (B); Polese 2012 (C); Santo Silva 2009 (D); Yin 2006 (E); Planes 2010 (F)


Range of sensitivities Type 3 HSAT: 0.62 to 0.94 | Range of specificities Type 3 HSAT: 0.25 to 0.97 Range of sensitivities Attended PSG: 1.00 to 1.00 | Range of specificities Attended PSG: 1.00 to 1.00 Accuracy (high risk): 65% to 91% Accuracy (low risk): 59% to 90%

	Quality of the	Number	Number of				
Test result	Evidence	Prevalence 64%		Prevale	participants		
	(GRADE)	Type 3 HSAT	Attended PSG	Type 3 HSAT	Attended PSG	(studies)	
True positivos		397 to 602	640 to 640	155 to 235	250 to 250		
True positives (patients with OSA)	$\oplus \oplus \oplus \bigcirc$	38 to 243 fewer TP in Type 3 HSAT		15 to 95 fewer 1 HSAT		457_	
False negatives	MODERATE ¹	38 to 243	0 to 0	15 to 95	0 to 0	6) ^{A-F}	
(patients incorrectly classified as not having OSA)		38 to 243 more HSAT	FN in Type 3	15 to 95 more F HSAT			
True negatives		90 to 349	360 to 360	188 to 728	750 to 750		
(patients without OSA)	$\oplus \oplus \oplus \bigcirc$	11 to 270 fewer TN in Type 3 HSAT		22 to 562 fewer TN in Type 3 HSAT		457	
False positives	MODERATE ¹	11 to 270	0 to 0	22 to 562	0 to 0	(6) ^{A-F}	
(patients incorrectly classified as having OSA)		11 to 270 more FP in Type 3 HSAT		22 to 562 more FP in Type 3 HSAT			
¹ Wide range of values	s for specificity and	sensitivity					

Figure S16—Type 3 HSAT vs. PSG (AHI ≥ 30)

Study	ТР	FP	FN	TN	Sensitivity (95% CI)
Garcia-Diaz 2007	23	2	2	35	0.92 [0.74, 0.99]
Gjevre 2011	2	0	6	39	0.25 [0.03, 0.65]
Masa 2011	174	90	11	73	0.94 [0.90, 0.97]
Planes 2010	9	1	3	32	0.75 [0.43, 0.95]
Polese 2012	25	2	6	10	0.81 [0.63, 0.93]

Pooled sensitivity: 0.87 [0.77, 0.93] Pooled specificity: 0.88 [0.59, 0.97] DOR: 49.0 [13.9, 172.2] LR+: 7.06 [1.88, 26.6] LR-: 0.14 [0.08, 0.25] Accuracy: 0.77 or <u>77%</u>






Figure S17—ROC Curve for Type 3 HSAT vs. PSG (AHI ≥ 30)

Table S41—Summary of Findings table for Type 3 HSAT vs. PSG to diagnose OSA in Suspected Adults (AHI \ge 30)

References: Garcia-Diaz 2007 (A); Gjevre 2011 (B); Masa 2011 (C); Planes 2010 (D); Polese 2012 (E)

Pooled sensitivity Type 3 HSAT: 0.87 (95% CI: 0.77 to 0.93) | Pooled specificity Type 3 HSAT: 0.88 (95% CI: 0.59 to 0.97) Pooled sensitivity Attended PSG: 1.00 (95% CI: 1.00 to 1.00) | Pooled specificity Attended PSG: 1.00 (95% CI: 1.00 to 1.00) Accuracy (high risk): 88% (95% CI: 81 to 94%) Accuracy (low risk): 88% (95% CI: 71 to 95%)

		Number of re	Number of			
Test result	Quality of the Evidence (GRADE)	Prevalen	ce 36%	Prevalence 10%		participants
	, , , , , , , , , , , , , , , , , , ,	Type 3 HSAT	Attended PSG	Type 3 HSAT	Attended PSG	⁻ (studies)
True positives (patients with OSA)		313 (277 to 335)	360 (360 to 360)	87 (77 to 93)	100 (100 to 100)	
	$\oplus \oplus \bigcirc \bigcirc$	47 fewer TP in HSAT	Туре 3	13 fewer TP in Type 3 HSAT		545
False negatives	LOW ^{1,2}	47 (25 to 83)	0 (0 to 0)	13 (7 to 23)	0 (0 to 0)	(5) ^{A-E}
(patients incorrectly classified as not having OSA)		47 more FN in Type 3 HSAT		13 more FN in Type 3 HSAT		
True negatives		563 (378 to 621)	640 (640 to 640)	792 (531 to 873)	900 (900 to 900)	
(patients without OSA)	$\oplus \oplus \bigcirc \bigcirc$	77 fewer TN in Type 3 HSAT		108 fewer TN in Type 3 HSAT		545
False positives (patients incorrectly classified as having OSA)	LOW ^{1,2}	77 (19 to 262)	0 (0 to 0)	108 (27 to 369)	0 (0 to 0)	- (5) ^{A-E}
		77 more FP in Type 3 HSAT		108 more FP in Type 3 HSAT		

Table S42—Summary of Findings table for 2-3 Channel HSAT vs. PSG to diagnose OSA in Suspected Adults (AHI \ge 5)

References: Ayappa 2008 (A); Tonelli de Oliveria 2009 (B); Ward 2015 (C)

Range of sensitivities 2-3 Channel HSAT: 0.80 to 0.96 | Range of specificities 2-3 Channel HSAT: 0.65 to 0.83 Range of sensitivities Attended PSG: 1.00 to 1.00 | Range of specificities Attended PSG: 1.00 to 1.00 Accuracy (high risk): 81% to 93% Accuracy (low risk): 77% to 88%

		Number of re	Number of			
Test result	Quality of the Evidence (GRADE)	Prevalen	ce 36%	Prevalence 10%		participants
		2-3 Channel HSAT	Attended PSG	2-3 Channel HSAT	Attended PSG	(studies)
True positives (patients with OSA)		696 to 835	870 to 870	440 to 528	550 to 550	
	⊕⊕⊕⊖ MODERATE ¹	35 to 174 fewer TP in 2-3 Channel HSAT		22 to 110 fewer TP in 2-3 Channel HSAT		292 (3) ^{A-C}
False negatives		35 to 174	0 to 0	22 to 110	0 to 0	
(patients incorrectly classified as not having OSA)		35 to 174 more FN in 2-3 Channel HSAT		22 to 110 more FN in 2-3 Channel HSAT		
True negatives		85 to 108	130 to 130	293 to 373	450 to 450	
(patients without OSA)	⊕⊕⊕⊖ MODERATE ¹		22 to 45 fewer TN in 2-3 Channel HSAT		77 to 157 fewer TN in 2-3 Channel HSAT	
False positives (patients incorrectly classified as having OSA)		22 to 45	0 to 0	77 to 157	0 to 0	(3) ^{A-C}
		22 to 45 more FP in 2-3 Channel HSAT		77 to 157 more FP in 2-3 Channel HSAT		
¹ Wide range of sensitivity						

Table S43—Summary of Findings table for 2-3 Channel HSAT vs. PSG to diagnose OSA in Suspected Adults (AHI \ge 15)

References: Ayappa 2008 (A); Baltzan 2000 (B); Masdeu 2010 (C); Tonelli de Oliveria 2009 (D); Ward 2015 (E)

Range of sensitivities 2-3 Channel HSAT: 0.66 to 0.88 | Range of specificities 2-3 Channel HSAT: 0.62 to 1.00 Range of sensitivities Attended PSG: 1.00 to 1.00 | Range of specificities Attended PSG: 1.00 to 1.00 Accuracy (high risk): 72% to 87% Accuracy (low risk): 68% to 95%

	-	Number of	-			
Test result	Quality of the Evidence	Prevalen	ce 36%	Prevale	Number of participants	
	(GRADE)	2-3 Channel HSAT	Attended PSG	2-3 Channel HSAT	Attended PSG	(studies)
True positives (patients with OSA)		422 to 563	640 to 640	165 to 220	250 to 250	
	⊕⊕⊕⊖ MODERATE ¹	77 to 218 fewer TP in 2-3 Channel HSAT		30 to 85 fewer TP in 2-3 Channel HSAT		443
False negatives		77 to 218	0 to 0	30 to 85	0 to 0	(5) ^{A-E}
(patients incorrectly classified as not having OSA)		77 to 218 more FN in 2-3 Channel HSAT		30 to 85 more F Channel HSAT		
True negatives		223 to 360	360 to 360	465 to 750	750 to 750	
(patients without OSA)	$\oplus \oplus \oplus \bigcirc$	0 to 137 fewer TN in 2-3 Channel HSAT		0 to 285 fewer 1 Channel HSAT	443	
False positives	MODERATE ¹	22 to 137	0 to 0	0 to 285	0 to 0	(5) ^{A-E}
(patients incorrectly classified as having OSA)		0 to 137 more FP in 2-3 Channel HSAT		0 to 285 more FP in 2-3 Channel HSAT		
¹ Wide range of sensiti	vity and specificit	y				

Table S44—Summary of Findings table for 2-3 Channel HSAT vs. PSG to diagnose OSA in Suspected Adults (AHI \ge 30)

References: Tonelli de Oliveria 2009 (A); Ward 2015 (B)

Range of sensitivities 2-3 Channel HSAT: 0.78 to 0.90 | Range of specificities 2-3 Channel HSAT: 0.92 to 0.98 Range of sensitivities Attended PSG: 1.00 to 1.00 | Range of specificities Attended PSG: 1.00 to 1.00 Accuracy (high risk): 71% to 90% Accuracy (low risk): 88% to 91%

		Number	Number of			
Test result	Quality of the Evidence	Prevalen	ce 36%	Prevalen	participants	
	(GRADE)	2-3 Channel HSAT	Attended PSG	2-3 Channel HSAT	Attended PSG	(studies)
True positives	155 to 288	360 to 360	43 to 80	100 to 100		
(patients with OSA)		72 to 205 fewer TP in 2-3 Channel HSAT		20 to 57 fewer TP HSAT	in 2-3 Channel	205
False negatives	⊕⊕⊕⊕ HIGH	72 to 205	0 to 0	20 to 57	0 to 0	- 225 (2) ^{A-B}
(patients incorrectly classified as not having OSA)		72 to 205 more FN in 2-3 Channel HSAT		20 to 57 more FN HSAT		
True negatives		589 to 627	640 to 640	828 to 882	900 to 900	
(patients without OSA)		13 to 51 fewer TN in 2-3 Channel HSAT		18 to 72 fewer TN HSAT		
False positives	⊕⊕⊕⊕ HIGH	13 to 51	0 to 0	18 to 72	0 to 0	225 (2) ^{A-B}
(patients incorrectly classified as having OSA)		13 to 51 more FP in 2-3 Channel HSAT		18 to 72 more FP HSAT		

Table S45—Summary of Findings table for 2-3 Channel HSAT vs. In-home PSG to diagnose OSA in Suspected Adults (AHI ≥ 15)

References: Gantner 2010 (A)

Single study sensitivity 2-3 Channel HSAT: 0.88 (95% CI: 0.80 to 0.93) | Single study specificity 2-3 Channel HSAT: 0.84 (95% Cl: 0.69 to 0.93) Single study sensitivity In-home PSG: 1.00 (95% Cl: 1.00 to 1.00) | Single study specificity In-home PSG: 1.00 (95% Cl: 1.00 to 1.00) 1.00 (95% Cl: 1.00 to 1.00) 1.00 (95% Cl: 1.00 to 1.00) Accuracy (high risk): 86% (95% Cl: 76 to 93%) Accuracy (low risk): 85% (95% Cl: 72 to 93%)

		Number	95% CI)	Number of		
Test result	Quality of the Evidence	Prevalen	ce 64%	Prevalen	participants	
	(GRADE)	2-3 Channel HSAT	In-home PSG	2-3 Channel HSAT	In-home PSG	(studies)
True positives (patients with		563 (512 to 595)	640 (640 to 640)	220 (200 to 233)	o 233) 250 (250 to 250)	
ÖSA)	0000	77 fewer TP in 2-3	Channel HSAT	30 fewer TP in 2-3	3 Channel HSAT	140
False negatives	$ \bigoplus \bigoplus \bigcirc \bigcirc \\ LOW^{1,2} $	77 (45 to128)	0 (0 to 0)	30 (50 to 17)	0 (0 to 0)	143 (1) ^A
(patients incorrectly classified as not having OSA)		77 more FN in 2-3 Channel HSAT		30 more FN in 2-3 Channel HSAT		
True negatives		302 (248 to 335)	360 (360 to 360)	630 (518 to 698)	750 (750 to 750)	
(patients without OSA)	$\oplus \oplus \bigcirc \bigcirc$	58 fewer TN in 2-3 Channel HSAT		120 fewer TN in 2-3 Channel HSAT		143
False positives	LOW ^{1,2}	58 (25 to 112)	0 (0 to 0)	120 (52 to 232)	0 (0 to 0)	(1) ^A
(patients incorrectly classified as having OSA)		58 more FP in 2-3 Channel HSAT		120 more FP in 2-3 Channel HSAT		

¹Indirect evidence as study only included Chinese population at high cardiovascular risk ²Wide confidence interval for specificity

Table S46—Summary of Findings table for 2-3 Channel HSAT vs. in-home PSG to diagnose OSA in Suspected Adults (AHI \ge 30)

References: Chai-Coetzer 2010 (A); Gantner 2010 (B)

Range of sensitivities 2-3 Channel HSAT: 0.84 to 0.97 | Range of specificities 2-3 Channel HSAT: 0.82 to 0.87 Range of sensitivities In-home PSG: 1.00 to 1.00 | Range of specificities In-home PSG: 1.00 to 1.00 Accuracy (high risk): 83% to 91% Accuracy (low risk): 82% to 88%

		Number				
Test result	Quality of the Evidence	Prevaler	nce 36%	Prevalen	Number of participants	
	(GRADE)	2-3 Channel HSAT	In-home PSG	2-3 Channel HSAT	In-home PSG	(studies)
True positives		302 to 349	360 to 360	84 to 97	100 to 100	
(patients with OSA)		11 to 58 fewer TP in 2-3 Channel HSAT		3 to 16 fewer TP in HSAT	n 2-3 Channel	
False negatives	⊕⊕⊕⊕ HIGH	11 to 58	0 to 0	3 to 16	0 to 0	- 300 (2) ^{A,B}
(patients incorrectly classified as not having OSA)		11 to 58 more FN in 2-3 Channel HSAT		3 to 16 more FN in 2-3 Channel HSAT		
True negatives		525 to 557	640 to 640	738 to 783	900 to 900	
(patients without OSA)		83 to 115 fewer TN in 2-3 Channel HSAT		117 to 162 fewer T Channel HSAT		
False positives	⊕⊕⊕⊕ HIGH	83 to 115	0 to 0	117 to 162	0 to 0	- 300 (2) ^{A,B}
(patients incorrectly classified as having OSA)		83 to 115 more FP in 2-3 Channel HSAT		117 to 162 more F Channel HSAT		

Table S47—Summary of Findings table for Single Channel HSAT vs. PSG to diagnose OSA in Suspected Adults (AHI \ge 5)

References: Nakano 2008 (A)

Single study sensitivity Single Channel HSAT: 0.96 (95% CI: 0.91 to 1.00) | Single study specificity Single Channel HSAT: 0.82 (95% CI: 0.60 to 1.00) Single study sensitivity Attended PSG: 1.00 (95% CI: 1.00 to 1.00) | Single study specificity Attended PSG: 1.00 (95% CI: 1.00 to 1.00) Accuracy (high risk): 94% (95% CI: 87 to 100%) Accuracy (low risk): 90% (95% CI: 77 to 100%)

		Number	Number of			
Test result	Quality of the Evidence	Prevalen	ce 87%	Prevalen	participants	
	(GRADE)	Single Channel HSAT	Attended PSG	Single Channel HSAT	Attended PSG	(studies)
rue positives		835 (792 to 870)	870 (870 to 870)	528 (501 to 550)	550 (550 to 550)	
(patients with OSA)	⊕⊕⊕⊖	35 fewer TP in Sin HSAT	ngle Channel	22 fewer TP in Sir HSAT	100 (1) ^A	
False negatives	MODERATE ¹	35 (0 to78)	0 (0 to 0) 22 (0 to 49) 0			0 (0 to 0)
(patients incorrectly classified as not having OSA)		35 more FN in Single Channel HSAT		22 more FN in Single Channel HSAT		
True negatives		107 (78 to 130)	130 (130 to 130)	369 (270 to 450)	450 (450 to 450)	
(patients without OSA)	⊕⊕⊕⊖	23 fewer TN in Single Channel HSAT		81 fewer TN in Si HSAT	100	
False positives (patients incorrectly classified as having OSA)	MODERATE ¹	23 (0 to 52)	0 (0 to 0)	81 (0 to180)	0 (0 to 0)	- (1) ^A
		23 more FP in Single Channel HSAT		81 more FP in Sir HSAT		

Table S48—Summary of Findings table for Single Channel HSAT vs. PSG to diagnose OSA in Suspected Adults (AHI \ge 15)

References: Nakano 2008 (A); Ozmen 2011 (B); Pang 2006 (C); Watkins 2009 (D)

Range of sensitivities Single-Channel HSAT: 0.55 to 0.91 | Range of specificities Single-Channel HSAT: 0.70 to 0.82 Range of sensitivities Attended PSG: 1.00 to 1.00 | Range of specificities Attended PSG: 1.00 to 1.00 Accuracy (high risk): 60% to 88% Accuracy (low risk): 66% to 84%

		Number o	(95% CI)			
Test result	Quality of the Evidence	Prevalen	ce 64%	Prevaler	Number of participants	
	(GRADE)	Single-Channel HSAT	Attended PSG	Single-Channel HSAT	Attended PSG	(studies)
True positives		352 to 582	640 to 640	138 to 228	250 to 250	
(patients with OSA)	(patients with		58 to 288 fewer TP in Single- Channel HSAT		P in Single-	005
False negatives $\bigoplus \bigoplus \bigoplus \bigoplus$ MODERATE1		58 to 288	0 to 0	22 to 112	0 to 0	- 235 (4) ^{A-D}
(patients incorrectly classified as not having OSA)		58 to 288 more FN in Single- Channel HSAT		22 to 112 more FN in Single- Channel HSAT		
True negatives		252 to 295	360 to 360	525 to 615	750 to 750	
(patients without OSA)		65 to108 fewer TN in Single- Channel HSAT		135 to 225 fewer Channel HSAT		
False positives	$\bigoplus \bigoplus \bigoplus \bigcirc \bigcirc$ MODERATE ¹	65 to 108	0 to 0	135 to 225	0 to 0	- 235 (4) ^{A-D}
(patients incorrectly classified as having OSA)		65 to108 more FP in Single- Channel HSAT		135 to 225 more FP in Single- Channel HSAT		
¹ Wide range of value	ues for sensitivity					

Table S49—Summary of Findings table for Single Channel HSAT vs. PSG to diagnose OSA in Suspected Adults (AHI \ge 30)

References: Nakano 2008 (A)

Single study sensitivity Single Channel HSAT: 0.89 (95% CI: 0.80 to 0.97) | Single study specificity Single Channel HSAT: 0.96 (95% CI: 0.90 to 1.00) Single study sensitivity Attended PSG: 1.00 (95% CI: 1.00 to 1.00) | Single study specificity Attended PSG: 1.00 (95% CI: 1.00 to 1.00) Accuracy (high risk): 93% (95% CI: 86 to 99%) Accuracy (low risk): 95% (95% CI: 88 to 100%)

		Number of results per 1000 patients tested (95% CI)						
Test result	Quality of the Evidence	Prevalen	ce 36%	Prevaler	Number of participants			
	(GRADE)	Single Channel HSAT	Attended PSG	Single Channel HSAT	Attended PSG	(studies)		
True positives (patients with		320 (288 to 349)	360 (360 to 360)	89 (80 to 97)	100 (100 to 100)			
OSA)	$\oplus \oplus \oplus \oplus$	40 fewer TP in Single Channel HSAT		11 fewer TP in S HSAT	ingle Channel	100		
False negatives	HIGH	40 (11 to 72)	0 (0 to 0)	11 (3 to 20)	0 (0 to 0)	(1) ^A		
(patients incorrectly classified as not having OSA)		40 more FN in Single Channel HSAT		11 more FN in Single Channel HSAT				
True negatives		614 (576 to 640)	640 (640 to 640)	864 (810 to 900)	900 (900 to 900)			
(patients without OSA)	patients without DSA) ⊕⊕⊕⊕		26 fewer TN in Single Channel HSAT		36 fewer TN in Single Channel HSAT			
False positives (patients incorrectly classified as having OSA)	HIGH	26 (0 to 64)	0 (0 to 0)	36 (0 to 90)	0 (0 to 0)	(1) ^A		
		26 more FP in Single Channel HSAT		36 more FP in Single Channel HSAT				

Table S50—Summary of Findings table for Other Single-Channel HSAT vs. PSG to diagnose OSA in Suspected Adults (AHI \ge 5)

References: Rofail 2010 (A)

Single study sensitivity Other Single-Channel HSAT: 0.80 (95% Cl: 0.67 to 0.93) | Single study specificity Other Single-Channel HSAT: 0.87 (95% Cl: 0.77 to 0.97) Single study sensitivity Attended PSG: 1.00 (95% Cl: 1.00 to 1.00) | Single study specificity Attended PSG: 1.00 (95% Cl: 1.00 to 1.00) | Single study specificity Attended PSG: 1.00 (95% Cl: 1.00 to 1.00) | Accuracy (high risk): 81% (95% Cl: 68 to 94%) Accuracy (low risk): 83% (95% Cl: 72 to 95%)

		Number o	of results per 100	0 patients tested ((95% CI)				
Test result	Quality of the Evidence	Prevalen	ce 87%	Prevaler	Prevalence 55%				
	(GRADE)	Other Single- Channel HSAT	Attended PSG	Other Single- Channel HSAT	Attended PSG	(studies)			
True positives (patients with		696 (583 to 809)	870 (870 to 870)	440 (369 to 512)	550 (550 to 550)				
OSA)	$\oplus \oplus \oplus \bigcirc$	174 fewer TP in C Channel HSAT	ther Single-	110 fewer TP in 0 Channel HSAT	Other Single-	92			
False negatives	MODERATE ¹	174 (61 to 287)	0 (0 to 0)	110 (38 to 181)	(1) ^A				
(patients incorrectly classified as not having OSA)		174 more FN in O Channel HSAT	ther Single-	110 more FN in 0 Channel HSAT					
True negatives		113 (100 to 126)	130 (130 to 130)	391 (347 to 436)	450 (450 to 450)				
(patients without OSA)	⊕⊕⊕⊖	17 fewer TN in Ot Channel HSAT	her Single-	59 fewer TN in O Channel HSAT	ther Single-	92			
False positives	MODERATE ¹	17 (4 to 30)	0 (0 to 0)	59 (14 to 103)	0 (0 to 0)	(1) ^A			
(patients incorrectly classified as having OSA)		17 more FP in Otl Channel HSAT	ner Single-	59 more FP in Of Channel HSAT	her Single-				
¹ Wide confidence	intervals for specifi	city and sensitivity							

Table S51—Summary of Findings table for Oximetry vs. In-home PSG to diagnose OSA in Suspected Adults (AHI \ge 5)

References: Chung 2012 (A)

Single study sensitivity Oximetry : 0.70 (95% CI: 0.66 to 0.76) | Single study specificity Oximetry : 0.90 (95% CI: 0.85 to 0.94)

Single study sensitivity In-home PSG: 1.00 (95% CI: 1.00 to 1.00) | Single study specificity In-home PSG: 1.00 (95% CI: 1.00 to 1.00) Accuracy (high risk): 73% (95% CI: 68 to 78%) Accuracy (low risk): 79% (95% CI: 74 to 84%)

	Quality of the	Number o	Number of results per 1000 patients tested (95% CI)								
Test result	Evidence	Prevalen	ce 87%	Prevaler	Number of participants						
	(GRADE)	Oximetry	In-home PSG	Oximetry	In-home PSG	(studies)					
True positives (patients with OSA)		609 (574 to 661)	870 (870 to 870)	385 (363 to 418)	550 (550 to 550)						
(patients with OSA)	$\oplus \oplus \oplus \bigcirc$	261 fewer TP in O	ximetry	165 fewer TP in	Oximetry	243					
False negatives	MODERATE ¹	261 (209 to 296)	0 (0 to 0)	165 (132 to187)	0 (0 to 0)	(1) ^A					
(patients incorrectly classified as not having OSA)		261 more FN in O	ximetry	165 more FN in (
True negatives (patients without		117 (111 to 122) 130 (130 to 130)		405 (382 to 423) 450 (450 to 450)							
ÔSA)	$\oplus \oplus \oplus \bigcirc$	13 fewer TN in Ox	imetry	45 fewer TN in O	243						
False positives	MODERATE ¹	13 (8 to19)	0 (0 to 0)	45 (27 to 68)	0 (0 to 0)	(1) ^A					
(patients incorrectly classified as having OSA)		13 more FP in Ox	imetry	45 more FP in O							
¹ Indirect evidence as	study only includ	ed patients schedule	ed for inpatient su	rgery							

Table S52—Summary of Findings table for Oximetry vs. In-home PSG to diagnose OSA in Suspected Adults (AHI \ge 15)

References: Chung 2012 (A)

Single study sensitivity Oximetry: 0.93 (95% Cl: 0.90 to 0.97) | Single study specificity Oximetry: 0.75 (95% Cl: 0.70 to 0.80)

Single study sensitivity In-home PSG: 1.00 (95% CI: 1.00 to 1.00) | Single study specificity In-home PSG: 1.00 (95% CI: 1.00 to 1.00) Accuracy (high risk): 86% (95% CI: 83 to 91%) Accuracy (low risk): 80% (95% CI: 75 to 84%)

	Quality of the	Number o	Number of results per 1000 patients tested (95% CI)								
Test result	Evidence	Prevalen	ce 64%	Prevaler	Number of participants						
	(GRADE)	Oximetry	In-home PSG	Oximetry	In-home PSG	(studies)					
True positives (patients with OSA)		595 (576 to 621)	640 (640 to 640)	233 (225 to 243)	250 (250 to 250)						
(patients with OSA)	$\oplus \oplus \oplus \bigcirc \bigcirc$	45 fewer TP in Ox	imetry	17 fewer TP in O	ximetry	243					
False negatives	MODERATE ¹	45 (19 to 64)	0 (0 to 0)	0 (0 to 0)	(1) ^A						
(patients incorrectly classified as not having OSA)		45 more FN in Ox	ximetry								
True negatives (patients without		270 (252 to 288)	360 (360 to 360)	563 (525 to 600)	750 (750 to 750)						
ÔSA)	$\oplus \oplus \oplus \bigcirc$	90 fewer TN in Ox	imetry	187 fewer TN in	187 fewer TN in Oximetry						
False positives	MODERATE ¹	90 (72 to108)	0 (0 to 0)	187 (150 to 225)	0 (0 to 0)	(1) ^A					
(patients incorrectly classified as having OSA)		90 more FP in Ox	imetry	187 more FP in C	Dximetry						
¹ Indirect evidence as	study included pa	atients scheduled for	r inpatient surgery								

Table S53—Summary of Findings table for Oximetry vs. In-home PSG to diagnose OSA in Suspected Adults (AHI \ge 30)

References: Chung 2012 (A)

Single study sensitivity Oximetry: 1.00 (95% CI: 1.00 to 1.00) | Single study specificity Oximetry: 0.59 (95% CI: 0.54 to 0.63)

Single study sensitivity In-home PSG: 1.00 (95% CI: 1.00 to 1.00) | Single study specificity In-home PSG: 1.00 (95% CI: 1.00 to 1.00) Accuracy (high risk): 74% (95% CI: 71 to 76%) Accuracy (low risk): 63% (95% CI: 59 to 67%)

	Quality of the	Number o	of results per 100	Number of results per 1000 patients tested (95% CI)								
Test result	Evidence	Prevalen	ce 36%	Prevaler	Number of participants							
	(GRADE)	Oximetry	In-home PSG	Oximetry	In-home PSG	(studies)						
True positives		360 (360 to 360)	360 (360 to 360)	100 (100 to 100)	100 (100 to 100)							
(patients with OSA)	$\oplus \oplus \oplus \bigcirc$	0 fewer TP in Oxi	netry	0 fewer TP in Ox	imetry	243						
False negatives	MODERATE ¹	0 (0 to 0)	0 (0 to 0)	(1) ^A								
(patients incorrectly classified as not having OSA)		0 fewer FN in Oxi	metry	0 fewer FN in Ox								
True negatives (patients without		378 (346 to 403) 640 (640 to 640)		531 (486 to 567) 900 (900 to 900)								
ÖSA)	$\oplus \oplus \oplus \bigcirc$	262 fewer TN in O	ximetry	369 fewer TN in	243							
False positives	MODERATE ¹	262 (237 to 294)	0 (0 to 0)	369 (333 to 414)	0 (0 to 0)	(1) ^A						
(patients incorrectly classified as having OSA)		262 more FP in O	ximetry	369 more FP in C	Dximetry							
¹ Indirect evidence as	study includes pa	atients scheduled for	r inpatient surgery									

Table S54—Summary of Findings table for Watch-Peripheral Arterial Tone (Watch-PAT) vs. In-Home PSG to diagnose OSA in Suspected Adults (AHI \ge 5)

References: O'Brien 2012 (A)

Single study sensitivity Watch-PAT: 0.88 (95% CI: 0.47 to 1.00) | Single study specificity Watch-PAT: 0.87 (95% CI: 0.66 to 0.97) Accuracy (high risk): 88% (95% CI: 50 to 100%) Accuracy (low risk): 88% (95% CI: 55 to 99%)

	Quality of	Number	of results per 100	0 patients tested	(95% CI)	Number of				
Test result	the Evidence	Prevale	nce 87%	Prevaler	participants					
	(GRADE)	Watch-PAT	In-Home PSG	Watch-PAT	In-Home PSG	(studies)				
True positives		766 (409 to 870)	870 (870 to 870)	484 (259 to 550 (550 to 550) 550)						
(patients with OSA)	$\oplus \oplus \oplus \bigcirc$	104 fewer TP in	Watch-PAT	66 fewer TP in V	Vatch-PAT	31				
False negatives	MODERATE ¹	E ¹ 104 (0 to 461) 0 (0 to 0) 66 (0 to 291) 0 (0 to 0)		0 (0 to 0)	(1) ^A					
(patients incorrectly classified as not having OSA)		104 more FN in \	Watch-PAT	66 more FN in V						
True negatives (patients without		113 (86 to 126) 130 (130 to 130)		391 (297 to450 (450 to436)450)						
ÖSA)	⊕⊕⊕⊖	17 fewer TN in W	/atch-PAT	59 fewer TN in V	31					
False positives	MODERATE ¹	17 (4 to 44)	0 (0 to 0)	59 (14 to 153)	0 (0 to 0)	(1) ^A				
(patients incorrectly classified as having OSA)		17 more FP in W	atch-PAT	59 more FP in V	/atch-PAT					
¹ Wide confidence intervals for sensitivity and specificity										

Table S55—Summary of Findings table for Watch-PAT vs. In-lab PSG to diagnose OSA in Suspected Adults (AHI \ge 5)

References: Garg 2014 (A)

Single study sensitivity Watch-PAT: 0.96 (95% CI: 0.85 to 0.99) | **Single study specificity Watch-PAT**: 0.43 (95% CI: 0.22 to 0.66) **Accuracy (high risk)**: 89% (95% CI: 77 to 95%) **Accuracy (low risk)**: 72% (95% CI: 57 to 84%)

Quality of	Number	Number of			
the Evidence	Prevaler	nce 87%	Prevaler	participants	
(GRADE)	Watch-PAT	In-Home PSG	Watch-PAT	In-Home PSG	(studies)
	835 (739 to 861)	870 (870 to 870)	528 (468 to 545)	550 (550 to 550)	
$\Theta \Theta \Theta \odot$	35 fewer TP in W	atch-PAT	22 fewer TP in V	Vatch-PAT	75
MODERATE ¹			(1) ^A		
	35 more FN in W	atch-PAT	22 more FN in W		
	56 (29 to 86)	130 (130 to 130)	193 (99 to 297)	450 (450 to 450)	
$\Theta \Theta \Theta \odot$	74 fewer TN in W	atch-PAT	257 fewer TN in	75	
MODERATE ¹	74 (44 to 101)	0 (0 to 0)	257 (153 to 351)	0 (0 to 0)	(1) ^A
	74 more FP in W	atch-PAT	257 more FP in		
	the Evidence (GRADE) $\oplus \oplus \oplus \bigcirc$ MODERATE ¹	Image: constraint of the end of	the Evidence (GRADE) Prevalence 87% Watch-PAT In-Home PSG & 835 (739 to 861) 870 (870 to 870) 35 fewer TP in Watch-PAT 35 (9 to 131) 0 (0 to 0) 35 more FN in Watch-PAT 35 (9 to 131) 0 (0 to 0) \$6 (29 to 86) 130 (130 to 130) 130) ODERATE1 74 fewer TN in Watch-PAT 0 (0 to 0)	Prevalence Prevalence Prevalence (GRADE) Watch-PAT In-Home PSG Watch-PAT $Watch-PAT$ In-Home PSG Watch-PAT $\$35$ (739 to 861) $\$70$ (870 to $\$70$) $$528$ (468 to $$545$) $\$35$ fewer TP in Watch-PAT 22 fewer TP in V $\$35$ (9 to 131) 0 (0 to 0) 22 (5 to 82) 35 more FN in Watch-PAT 22 more FN in V $\$0$ (0 to 0) 56 (29 to 86) 130 (130 to 193 (99 to 297) $$74$ fewer TN in Watch-PAT 257 fewer TN in Monter TN in The TOPAT $$74$ (44 to 101) 0 (0 to 0) 257 (153 to 351)	the Evidence (GRADE) Prevalence 87% Prevalence 55% Watch-PAT In-Home PSG Watch-PAT In-Home PSG

Table S56—Summary of Findings table for Watch-PAT vs. In-lab PSG to diagnose OSA in Suspected Adults (AHI \ge 15)

References: Pittman 2004 (A); Garg 2014 (B)

Range of sensitivities Watch-PAT: 0.92 to 0.96 | Range of specificities Watch-PAT: 0.77 to 1.00 Accuracy (high risk): 84% to 97% Accuracy (low risk): 82% to 99%

	Quality of	Number o	of results per 10	00 patients tested (95% CI)	Number of
Test result	the Evidence	Prevalence	ce 64%	Prevalen	participants	
	(GRADE)	Watch-PAT	In-Lab PSG	Watch-PAT	In-Lab PSG	(studies)
True positives		589 to 614	640 to 640	230 to 240	250 to 250	
(patients with OSA)		26 to 51 fewer TP	in Watch-PAT	10 to 37 fewer TP	in Watch-PAT	
False negatives	$\oplus \oplus \oplus \bigcirc$ MODERATE ¹	26 to 51	0 to 0	10 to 20	0 to 0	104 (2) ^{A,B}
(patients incorrectly classified as not having OSA)	MODEIXATE	26 to 51 more FN	in Watch-PAT	10 to 20 more FN	in Watch-PAT	_ (_)
True negatives		277 to 360	360 to 360	578 to 750 750 to 750		
(patients without OSA)		0 to 83 fewer TN	in Watch-PAT	0 to 172 more TN	in Watch-PAT	
False positives	$\oplus \oplus \oplus \bigcirc$ MODERATE ¹	0 to 83	0 to 0	0 to 0 0 to 172 0 to 0		104 (2) ^{A,B}
(patients incorrectly classified as having OSA)	WODEINTE	0 to 83 more FP i	n Watch-PAT	0 to 172 more FP	in Watch-PAT	_ (-)
¹ Wide range of value	ues for specificity					

Table S57—Summary of Findings table for Watch-PAT vs. In-lab PSG to diagnose OSA in Suspected Adults (AHI \ge 30)

References: Pittman 2004 (A)

Single study sensitivity Watch-PAT: 0.92 (95% CI: 0.62 to 1.00) | **Single study specificity Watch-PAT**: 0.82 (95% CI: 0.57 to 0.96) **Accuracy (high risk)**: 83% (95% CI: 58 to 97%) **Accuracy (low risk)**: 83% (95% CI: 58 to 96%)

	Quality of the	Number of	results per 100	0 patients tested	(95% CI)	Number of				
Test result	Evidence	Prevalen	ce 36%	Prevaler	participant s					
	(GRADE)	Watch-PAT	In-Lab PSG	Watch-PAT	In-Lab PSG	(studies)				
True positives		331 (223 to 360)	360 (360 to 360)	92 (62 to 100)	100 (100 to 100)					
(patients with OSA)	$\oplus \oplus \oplus \bigcirc \bigcirc$	29 fewer TP in V	Vatch-PAT	8 fewer TP in W	atch-PAT	29				
False negatives	MODERATE ¹	29 (0 to 137)	0 (0 to 0)	8 (0 to 38)	0 (0 to 0)	(1) ^A				
(patients incorrectly classified as not having OSA)		29 more FN in V	Vatch-PAT	8 more FN in W						
True negatives (patients without		525 (365 to 614)	360 (360 to 360)	738 (513 to 864)	100 (100 to 100)					
ÖSA)	$\oplus \oplus \oplus \bigcirc \bigcirc$	165 more TN in	Watch-PAT	638 more TN in	Watch-PAT	29				
False positives	MODERATE ¹	115 (26 to 275)	0 (0 to)	162 (36 to 87)	0 (0 to 0)	(1) ^A				
(patients incorrectly classified as having OSA)		115 more FP in	Watch-PAT	162 more FP in	Watch-PAT					
¹ Wide confidence intervals for sensitivity and specificity										

Figure S18—HSAT vs. Attended PSG (ESS)

	H	SAT		F	PSG			Mean Difference		Mean Difference	
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI		IV, Random, 95% Cl	
Andreu 2012	5.5	4.5	39	6	4	20	9.6%	-0.50 [-2.75, 1.75]			
Antic 2009	4.02	4.7	90	4.2	4.6	84	25.4%	-0.18 [-1.56, 1.20]			
Berry 2008	6.5	4.4	40	7	4.4	39	12.9%	-0.50 [-2.44, 1.44]			
Kuna 2011	2.6	5.2	95	2.9	4.4	84	24.5%	-0.30 [-1.71, 1.11]			
Mulgrew 2007	8	5.9	31	10	5.9	30	5.5%	-2.00 [-4.96, 0.96]			
Rosen 2012	7	5.3	77	7.4	5.4	65	15.5%	-0.40 [-2.17, 1.37]			
Skomro 2010	6.5	5.2	33	6.1	6.3	37	6.7%	0.40 [-2.30, 3.10]			
Total (95% CI)			405			359	100.0%	-0.38 [-1.07, 0.32]		•	
Heterogeneity: Tau ² =	= 0.00; C	hi² =	1.59, d	f= 6 (P :	= 0.9	5); I² = I	0%		-10		10
Test for overall effect:	Z=1.08	i (P =	0.29)						-10	Favors HSAT Favors PSG	10

Figure S19—HSAT vs. PSG (QOL; FOSQ)

	H	SAT			PSG			Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI
Andreu 2012	18.5	1.5	17	18	2	20	20.6%	0.50 [-0.63, 1.63]	
Antic 2009	13.6	19	89	13.2	17.6	81	0.9%	0.40 [-5.10, 5.90]	
Kuna 2011	1.74	2.8	105	1.85	2.5	96	49.0%	-0.11 [-0.84, 0.62]	+
Rosen 2012	3.1	2.8	77	3.6	2.9	65	29.6%	-0.50 [-1.44, 0.44]	
Total (95% CI)			288			262	100.0%	-0.10 [-0.61, 0.42]	•
Heterogeneity: Tau² = Test for overall effect:			•	7= 3 (P =	= 0.61)); ² = 0°	%		-10 -5 0 5 10 Favors PSG Favors HSAT

Figure S20—HSAT vs. PSG (QOL; SAQLI)

Study or Subgroup		SAT	Total		SG	Total	Woight	Mean Difference IV, Random, 95% Cl	Mean Difference IV, Random, 95% Cl
Study of Subgroup	Mean	30	TUtai	wean	30	TULAI	weight	IV, Rahuom, 95% Ci	iv, Kalluolli, 95% Ci
Mulgrew 2007	1.9	1.4	31	2.2	1.6	30	12.0%	-0.30 [-1.06, 0.46]	
Rosen 2012	0.9	1.1	77	0.7	0.9	63	62.3%	0.20 [-0.13, 0.53]	-+■
Skomro 2010	4.6	1.1	33	4.5	1.1	37	25.7%	0.10 [-0.42, 0.62]	_ - _
Total (95% CI)			141			130	100.0%	0.11 [-0.15, 0.38]	+
Heterogeneity: Tau ² :	= 0.00; C	hi² =	1.42, df	'= 2 (P =	= 0.4	9); I 2 = 0	3%		
Test for overall effect	: Z = 0.86	6 (P =	0.39)						-2 -1 U 1 2 Favors PSG Favors HSAT

Figure S21—HSAT vs. PSG (QOL; SF-36 Vitality Score)

	H	ISAT			PSG			Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI
Antic 2009	16.1	20.5	89	15.3	18.5	81	24.7%	0.80 [-5.06, 6.66]	_
Rosen 2012	13.8	10.6	77	12.8	11	65	66.5%	1.00 [-2.57, 4.57]	-#-
Skomro 2010	64.1	18.4	33	62.2	23.3	37	8.9%	1.90 [-7.89, 11.69]	
Total (95% CI)			199			183	100.0%	1.03 [-1.88, 3.94]	◆
Heterogeneity: Tau² = Test for overall effect:			-	= 2 (P =	0.98);	I ^z = 0%			-20 -10 0 10 20 Favors PSG Favors HSAT

Figure S22—HSAT vs. PSG (QOL; SF-12/36 Physical Component Summary Score)

	н	SAT		F	SG			Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI
Kuna 2011	1.1	7.8	91	1.6	9	82	56.6%	-0.50 [-3.02, 2.02]	
Skomro 2010	51.7	8.1	33	47.7	9.3	37	43.4%	4.00 [-0.08, 8.08]	
Total (95% CI)			124			119	100.0%	1.45 [-2.92, 5.82]	
Heterogeneity: Tau ² = Test for overall effect:				f=1 (P =	= 0.07	7); I² = ;	70%		-10 -5 0 5 10 Favors PSG Favors HSAT

Figure S23—HSAT vs. PSG (QOL; SF-12/36 Mental Component Summary Score)

	H	ISAT			PSG			Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI
Antic 2009	4.8	13.8	89	5.1	19	81	20.6%	-0.30 [-5.33, 4.73]	
Kuna 2011	2.5	8.6	91	3	10.2	82	65.3%	-0.50 [-3.33, 2.33]	— — — — —
Skomro 2010	81.3	14.9	33	83.7	10.4	37	14.1%	-2.40 [-8.49, 3.69]	
Total (95% CI)			213			200	100.0%	-0.73 [-3.01, 1.56]	-
Heterogeneity: Tau² = Test for overall effect:				= 2 (P =	0.84);	I ^z = 0%	1		-10 -5 0 5 10 Favors PSG Favors HSAT

Figure S24—HSAT vs. PSG (CPAP Adherence, h/night)

	н	SAT		F	PSG			Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI
Antic 2009	4.11	2.7	94	4.56	2.7	83	16.4%	-0.45 [-1.25, 0.35]	
Berry 2008	5.2	1.8	40	5.25	2.4	39	13.8%	-0.05 [-0.99, 0.89]	-+-
Kuna 2011	3.5	2.5	96	2.9	2.3	86	18.5%	0.60 [-0.10, 1.30]	
Mulgrew 2007	6	1.5	31	5.4	2	30	14.6%	0.60 [-0.29, 1.49]	+
Rosen 2012	4.7	2.1	75	3.7	2.4	61	17.0%	1.00 [0.23, 1.77]	_ _
Skomro 2010	5.4	1	33	5.6	1.7	37	19.7%	-0.20 [-0.85, 0.45]	
Total (95% CI)			369			336	100.0%	0.25 [-0.21, 0.71]	•
Heterogeneity: Tau ² =	= 0.17; C	hi² =	10.45,	df = 5 (F	P = 0.0	06); I ^z =	52%		
Test for overall effect	Z=1.08	6 (P =	0.29)						Favors PSG Favors HSAT

Figure S25—HSAT vs. PSG (CPAP Adherence, no. nights > 4 h)

	HSA	Т	PSG	6		Odds Ratio	Odds Ratio	
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% CI	M-H, Random, 95% Cl	
Andreu 2012	93	129	44	66	21.1%	1.29 [0.68, 2.45]		
Berry 2008	24	40	22	39	10.8%	1.16 [0.47, 2.84]		
Kuna 2011	53	96	45	86	25.3%	1.12 [0.63, 2.01]	_ _	
Rosen 2012	72	163	46	134	38.8%	1.51 [0.94, 2.43]	⊢ ∎	
Skomro 2010	29	33	33	37	4.0%	0.88 [0.20, 3.83]		
Total (95% CI)		461		362	100.0%	1.29 [0.96, 1.73]	•	
Total events	271		190					
Heterogeneity: Tau ² =	0.00; Chi	i ^z = 0.91	7, df = 4 (P = 0.9	1); I ² = 09	6		-
Test for overall effect:	Z=1.70 ((P = 0.0	9)				0.05 0.2 1 5 20 Favors PSG Favors HSAT	

Table S58—HSAT compared to PSG for adults suspected of OSA

References: Andreu 2012 (A); Antic 2009 (B); Berry 2008 (C); Kuna 2011 (D); Mulgrew 2007 (E); Rosen 2012 (F); Skomro 2010 (G)

Setting: Home, lab Intervention: HSA Comparison: Atte	o NT	ected of OSA			
Outcomes	Quality of the evidence (GRADE)	Anticipated absolute et MD between HSAT and	· · ·	№ of participants (studies)	Comments
Sleepiness* (ESS)	⊕⊕⊕⊕ HIGH	The mean difference in s after treatment was 0.38 0.32 less) with HSAT	• • • •	764 (7 RCTs) ^{A-G}	
QOL (FOSQ)*	⊕⊕⊕⊕ HIGH	The mean difference in 0 treatment was 0.10 lowe lower) with HSAT	· · · ·	550 (4 RCTs) ^{A,B,D,F}	
QOL (SAQLI)*	⊕⊕⊕⊕ HIGH	The mean difference in 0 treatment was 0.11 grea 0.38 greater) with HSAT		271 (3 RCTs) ^{E,F,G}	
QOL (SF-36 Vitality Score)*	⊕⊕⊕⊕ HIGH	The mean difference in 0 Score) after treatment w lower to 3.94 greater) wi	as 1.03 greater (1.88	382 (3 RCTs) ^{B,F,G}	
QOL (SF- 12/SF-36 Physical Component Summary)*	⊕⊕⊕⊖ MODERATE ¹	The mean difference in C Physical Component Sur treatment was 1.45 grea 5.82 greater) with HSAT	mmary) after	243 (2 RCTs) ^{D,G}	
QOL (SF- 12/SF-36 Mental Component Summary)*	⊕⊕⊕⊖ MODERATE ¹	The mean difference in 0 Mental Component Sum was 0.73 lower (1.56 gre with HSAT	mary) after treatment	413 (3 RCTs) ^{B,D,G}	
CPAP Adherence (h/night)*	$ \begin{array}{c} \end{array} \\ \hline MODERATE^{2} \end{array} $	The mean CPAP Adhere intervention group was 0 less to 0.71 more) with F	.25 h more (0.21	705 (6 RCTs) ^{B-G}	
		Relative Effect Baseline Risk	Comparative risk		
	⊕⊕⊕⊕ HIGH	525 per 1000	588 per 1000 (515 to 656) OR 1.29 (0.96 to 1.73)	823 (5 RCTs) ^{A.C.D.F.G}	

¹Quality of evidence for QOL as measured by the SF-36 was downgraded due to imprecision (i.e., 95% CI of mean difference crosses clinical decision threshold of 3 points for SF-36 physical and mental component summary scores and the origin of the plot) ²Quality of evidence for adherence was downgraded due to imprecision (i.e., 95% CI of mean difference crosses clinical decision threshold of 0.5 h/night and the origin of the plot)

Table S59—Summary of Findings table for Multiple-night HSAT vs. Single-night HSAT to diagnose OSA in Suspected Adults (AHI \geq 5)

References: Rofail 2010 (A)

Single study sensitivity Multiple-night HSAT: 0.80 (95% CI: 0.67 to 0.93) | Single study specificity Multiple-night HSAT: 0.87 (95% CI: 0.77 to 0.97) Multiple-night HSAT Accuracy (high risk): 81% (95% CI: 68 to 94%) Multiple-night HSAT Accuracy (low risk): 83% (95% CI: 72 to 95%) Single study sensitivity Single-night HSAT: 0.75 (95% CI: 0.63 to 0.85) | Single study specificity Single-night HSAT: 0.79 (95% CI: 0.61 to 0.97) Single-night HSAT Accuracy (high risk): 76% (95% CI: 63 to 86%) Single-night HSAT Accuracy (low risk): 77% (95% CI: 62 to 90%)

	Nambe	r of results per 10	00 patients tested	(95% CI)	
Quality of the Evidence	Prevale	nce 87%	Prevaler	Number of participants	
(GRADE)	Multiple-night HSAT	Single-night HSAT	Multiple-night HSAT	Single-night HSAT	(studies)
	696 (583 to 809)	653 (548 to 739)	440 (369 to 512)	413 (347 to 468)	
	43 more TP in M HSAT	ultiple-night	27 more TP in Mu	ltiple-night HSAT	00
$\bigoplus \bigoplus \bigoplus \bigoplus \bigcirc$ MODERATE ¹	174 (61 to 287)	217 (131 to 322)	110 (38 to 181)	137 (82 to 203)	92 (1) ^A
	43 fewer FN in M HSAT	ultiple-night	27 fewer FN in Mu HSAT		
	113 (100 to 126)	103 (79 to 126)	391 (347 to 436)	356 (274 to 436)	
	10 more TN in M HSAT	ultiple-night	35 more TN in Mu HSAT	ltiple-night	00
$\Theta \Theta \Theta \odot$ MODERATE ¹	17 (4 to 30)	27 (4 to 51)	59 (14 to 103)	94 (14 to 176)	92 (1) ^A
	10 fewer FP in M HSAT	ultiple-night	35 fewer FP in Mu HSAT	Iltiple-night	
	(GRADE) ⊕⊕⊕⊖ MODERATE ¹ MODERATE ¹	Evidence (GRADE)Multiple-night HSATMultiple-night HSAT696 (583 to 809)43 more TP in Mu HSAT43 more TP in Mu HSAT174 (61 to 287)174 (61 to 287)43 fewer FN in M HSAT113 (100 to 126)10 more TN in Mu HSAT113 (100 to 126)10 more TN in Mu HSAT17 (4 to 30)10 fewer FP in M HSAT10 fewer FP in M HSAT	Evidence (GRADE) Multiple-night HSAT Single-night HSAT 696 (583 to 809) 653 (548 to 739) 43 more TP in Multiple-night HSAT 43 more TP in Multiple-night HSAT 174 (61 to 287) 217 (131 to 322) 43 fewer FN in Multiple-night HSAT 113 (100 to 126) 113 (100 to 126) 103 (79 to 126) 10 more TN in Multiple-night HSAT 17 (4 to 30) 27 (4 to 51) 10 fewer FP in Multiple-night	Evidence (GRADE)Multiple-night HSATSingle-night HSATMultiple-night HSAT $\oplus \oplus $	Evidence (GRADE)Multiple-night HSATSingle-night HSATMultiple-night HSATSingle-night HSAT $\ensuremath{\oplus}\oplus\oplus\oplus\oplus$ MODERATE1696 (583 to 809)653 (548 to 739)440 (369 to 512)413 (347 to 468) $\ensuremath{\oplus}\oplus\oplus\oplus\oplus$ MODERATE143 more TP in Multiple-night HSAT27 more TP in Multiple-night HSAT27 more TP in Multiple-night HSAT $\ensuremath{\oplus}\oplus\oplus\oplus\oplus$ MODERATE1174 (61 to 287)217 (131 to 322)110 (38 to 181)137 (82 to 203) 43 fewer FN in Multiple-night HSAT27 fewer FN in Multiple-night HSAT137 (82 to 203) 13 (100 to 126)103 (79 to 126)391 (347 to 436)356 (274 to 436) 13 (100 to 126)103 (79 to 126)391 (347 to 436)356 (274 to 436) 13 (100 to 126)103 (79 to 126)391 (347 to 436)356 (274 to 436) 13 (100 to 126)103 (79 to 126)391 (347 to 436)356 (274 to 436) 13 (100 to 126)103 (79 to 126)391 (347 to 436)356 (274 to 436) 13 (100 to 126)103 (79 to 126)391 (347 to 436)356 (274 to 436) 13 (100 to 126)103 (79 to 126)391 (347 to 436)394 (14 to 176) 13 (10 to 30)27 (4 to 51)59 (14 to 103)94 (14 to 176) 13 (10 fewer FP in Multiple-night HSAT35 fewer FP in Multiple-night HSAT35 fewer FP in Multiple-night

Wide confidence intervals for sensitivity and specificity

Table S60—Summary of Findings table for Multiple-night HSAT vs. Single-night HSAT to diagnose OSA in Suspected Adults (AHI \ge 30)

References: Rofail 2010 (A)

Single study sensitivity Multiple-night HSAT: 0.90 (95% Cl: 0.83 to 0.98) | Single study specificity Multiple-night HSAT: 0.85 (95% Cl: 0.78 to 0.89) Multiple-night HSAT Accuracy (high risk): 87% (95% Cl: 80 to 92%) Multiple-night HSAT Accuracy (low risk): 86% (95% Cl: 78 to 90%) Single study sensitivity Single-night HSAT: 0.90 (95% Cl: 0.84 to 0.98) | Single study specificity Single-night HSAT: 0.83 (95% Cl: 0.76 to 0.87) Single-night HSAT Accuracy (high risk): 86% (95% Cl: 77 to 91%) Single-night HSAT Accuracy (low risk): 84% (95% Cl: 78 to 88%)

		Number of rea	Number of results per 1000 patients tested (95% CI)					
Test result	Quality of the	Prevalence	ce 36%	Prevaler	nce 10%	Number of		
Test result	Evidence (GRADE)	Multiple-night HSAT	Single- night HSAT	Multiple- night HSAT	Single- night HSAT	participants (studies)		
True positives		324 (299 to 353)	324 (302 to 353)	90 (83 to 98)	90 (84 to 98)			
(patients with OSA)	$\oplus \oplus \oplus \oplus$	0 fewer TP in I night HSAT	Nultiple-	0 fewer TP in night HSAT	Multiple-	92		
False negatives	HIGH	36 (7 to 61)	36 (7 to 58)	10 (2 to17)	10 (2 to16)	(1) ^A		
(patients incorrectly classified as not having OSA)		0 fewer FN in I night HSAT	Multiple-	0 fewer FN in night HSAT	Multiple-			
True negatives		544 (499 to 570)	531 (486 to 557)	765 (702 to 801)	747 (684 to 783)			
(patients without OSA)	$\oplus \oplus \oplus \oplus$	13 more TN in Multiple- night HSAT		18 more TN in Multiple- night HSAT		92		
False positives (patients incorrectly classified as	HIGH	96 (70 to 141)	109 (83 to154)	135 (99 to198)	153 (117 to 216)	(1) ^A		
having OSA)		13 fewer FP in night HSAT	13 fewer FP in Multiple- night HSAT		n Multiple-			

Diagnosis of obstructive sleep apnea in adults with comorbid conditions

Table S61—Summary of Findings table for HSAT vs. PSG to diagnose OSA in Suspected Adults with comorbid conditions (AHI \ge 15)

References: Abraham 2006 (A); Series 2005 (B); de Vries 2015 (C)

Range of sensitivities HSAT: 0.64 to 0.93 | Range of specificities HSAT: 0.78 to 0.95 Range of sensitivities Attended PSG: 1.00 to 1.00 | Range of specificities Attended PSG: 1.00 to 1.00 Accuracy (high risk): 69% to 89% Accuracy (low risk): 74% to 92%

	Quality of the	Numbe	r of results per 10	00 patients test	ed (95% CI)	Number of	
Test result	Evidence (GRADE)	Preva	lence 64%	Preva	participants		
	(GRADE)	HSAT	Attended PSG	HSAT	Attended PSG	(studies)	
True positives		410 to 595	640 to 640	160 to 233	250 to 250		
(patients with OSA)		45 to 230 fewe	er TP in HSAT	17 to 90 fewer	TP in HSAT		
False negatives	⊕⊕⊖⊖ LOW ^{1,2}	45 to 230 0 to 0		17 to 90 0 to 0		190 (3 ^{A-C}	
(patients incorrectly classified as not having OSA)		45 to 230 mor	e FN in HSAT	17 to 90 more			
True negatives		281 to 342	360 to 360	585 to 712	750 to 750		
(patients without OSA)		18 to 79 fewer TN in HSAT		38 to 165 fewer TN in HSAT			
False positives	⊕⊕⊖⊖ LOW ^{1,2}	18 to 79	0 to 0	38 to 165 0 to 0		190 (3) ^{A-C}	
(patients incorrectly classified as having OSA)		18 to 79 more	FP in HSAT	38 to 165 mor	e FP in HSAT	,	

¹Wide range of values for sensitivity and specificity

²Indirectness as study populations not representative of all comorbid conditions typically associated with OSA

Diagnosis of obstructive sleep apnea in adults using a split-night versus a full-night polysomnography protocol

Table S62—Summary of Findings table for Split-night PSG vs. Full-night PSG to diagnose OSA in Suspected Adults (AHI \ge 5)

				Single study spe Accuracy (low risk					
Test result	Quality of the Evidence (GRADE)		Number of results per 1000 patients tested (95% CI) Prevalence 87% Prevalence 55% Split-night HSAT Split-night HSAT Full-night HSAT						
True positives (patients with OSA)		699 (583 to 783) 171 fewer TP in s	870 (870 to 870) split-night HSAT	442 (369 to 495) 108 fewer TP in s	550 (550 to 550) plit-night HSAT	_			
False negatives (patients incorrectly classified as not having OSA)	$\oplus \oplus \oplus \bigcirc$ MODERATE ¹	171 (87 to 287) 171 fewer FN in s	0 (0 to 0) split-night HSAT	108 (55 to 181) 108 more FN in s	0 (0 to 0) plit-night HSAT	114 _ (1) ^A			
True negatives		121 (108 to 127)	130 (130 to 130)	419 (373 to 441)	450 (450 to 450)				
(patients without OSA)		9 fewer TN in sp	lit-night HSAT	31 fewer TN in sp	lit-night HSAT				
False positives	$\oplus \oplus \oplus \bigcirc$ MODERATE ¹	9 (3 to 22)	0 (0 to 0)	31 (9 to 77)	0 (0 to 0)	114 (1) ^A			
(patients MODERATE incorrectly classified as having OSA)		9 more FP in spl	it-night HSAT	31 more FP in spl					

Table S63—Summary of Findings table for Split-night PSG vs. Full-night PSG to diagnose OSA in Suspected Adults (AHI \ge 15)

References: Khawja 2010 (A)

Single study sensitivity split-night HSAT: 0.77 (95% CI: 0.56 to 0.91) | **Single study specificity split-night HSAT**: 0.98 (95% CI: 0.92 to 1.00) **Accuracy (high risk)**: 85% (95% CI: 69 to 94%) **Accuracy (low risk)**: 93% (95% CI: 83 to 98%)

	Quality of the		r of results per 10	00 patients tested ((95% CI)	Number of
Test result	Evidence	Prevale	n ce 64%	Prevaler	participants	
	(GRADE)	Split-night HSAT	Full-night HSAT	Split-night HSAT	Full-night HSAT	(studies)
True positives		493 (358 to 582)	640 (640 to 640)	193 (140 to 228)	250 (250 to 250)	
(patients with OSA)		147 fewer TP in s	split-night HSAT	57 fewer TP in sp	lit-night HSAT	
False negatives (patients	$\oplus \oplus \oplus \bigcirc$ MODERATE ¹	147 (58 to 282)	0 (0 to 0)	57 (22 to 110)	0 (0 to 0)	114 (1) ^A
incorrectly classified as not having OSA)		147 more FN in s	split-night HSAT	57 more FN in spl		
True negatives		353 (331 to 359)	360 (360 to 360)	735 (690 to 748)	750 (750 to 750)	
(patients without OSA)		7 fewer TN in spl	lit-night HSAT	15 fewer TN in sp	lit-night HSAT	
False positives	$\oplus \oplus \oplus \bigcirc$ MODERATE ¹	7 (1 to 29)	0 (0 to 0)	15 (2 to 60)	0 (0 to 0)	114 (1) ^A
(patients MODERATE incorrectly classified as having OSA)		7 more FP in spl	it-night HSAT	15 more FP in spl		
¹ Wide confidence i	ntervals for sens	itivity				

Table S64—Summary of Findings table for Split-night PSG vs. Full-night PSG to diagnose OSA in Suspected Adults (AHI \ge 30)

References: Chou 2011 (A)

Single study sensitivity split-night HSAT: 0.90 (95% CI: not available) | Single study specificity split-night HSAT: 0.92 (95% CI: not available) Accuracy (high risk): 91% Accuracy (low risk): 92%

	Quality of the		Number of results per 1000 patients tested						
Test result	Evidence	Prevale	nce 36%	Prevaler	Number of participants				
	(GRADE)	Split-night HSAT	Full-night HSAT	Split-night HSAT	Full-night HSAT	(studies)			
True positives		324	360	90	100				
(patients with OSA)		36 fewer TP in sp	olit-night HSAT	10 fewer TP in sp	lit-night HSAT				
False negatives (patients	⊕⊕⊕⊕ HIGH	36	0	10	0	198 (1) ^A			
incorrectly classified as not having OSA)		36 more FN in sp	blit-night HSAT	10 more FN in spl					
True negatives		589	640	828	900				
(patients without OSA)		51 fewer TN in split-night HS		72 fewer TN in sp	lit-night HSAT				
False positives	ives ⊕⊕⊕⊕ HIGH	51	0	72	0	198 (1) ^A			
(patients incorrectly classified as having OSA)		51 more FP in sp	lit-night HSAT	72 more FP in spl	it-night HSAT				

Figure S26—Split-night PSG vs. Full-night PSG (Adherence, h/night)

	split-n	ight P	SG	full-ni	ght P	SG		Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI
Collen 2010	3.9	1.7	267	3.9	1.8	133	100.0%	0.00 [-0.37, 0.37]	
Total (95% CI)			267			133	100.0%	0.00 [-0.37, 0.37]	-
Heterogeneity: Not ap Test for overall effect:		(P = 1	.00)						-1 -0.5 0 0.5 1 Favors full-night PSG Favors split-night PSG

Figure S27—Split-night PSG vs. Full-night PSG (AHI after CPAP)

	split-night PSG			full-night PSG			Mean Difference		Mean Difference	
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI	
Collen 2010	6.1	11	397	7	12	397	22.3%	-0.90 [-2.50, 0.70]		
Yamashiro 1995	2.4	2.6	107	3	3.7	107	77.7%	-0.60 [-1.46, 0.26]		
Total (95% CI)			504			504	100.0%	-0.67 [-1.42, 0.09]	-	
Heterogeneity: Tau² = 0.00; Chi² = 0.10, df = 1 (P = 0.75); l² = 0% Test for overall effect: Z = 1.73 (P = 0.08)									-4 -2 0 2 4 Favors split-night PSG Favors full-night PSG	

Table S65—Summary of Findings table for split-night PSG vs. full-night PSG for the improvement in clinical outcomes of Adults suspected of OSA

References: Collen 2010 (A); Yamashiro 1995 (B)

Patient or population: adults suspected of OSA Setting: in-lab Intervention: split-night PSG Comparison: full-night PSG										
Outcomes	Quality of the evidence (GRADE)	Anticipated absolute effects [®] (95% Cl) MD between HSAT and PSG	№ of participants (studies)	Comments						
AHI*		The mean difference in AHI after treatment was 0.67 lower (1.42 lower to 0.09 higher) with split-night	504 (2 RCTs) ^{A,B}							
CPAP Adherence (h/night) *		The mean CPAP Adherence (h/night) in the split-night PSG group was 0.00 greater (0.37 fewer to 0.37 greater) with split-night PSG	400 (1 RCT) ^A							
*Critical Outcome	es									

¹Downgraded due to imprecision associated with a limited number of studies and small sample size

Repeat polysomnography for the diagnosis of obstructive sleep apnea in adults

Figure S28—Two-night PSG vs. Single-night PSG (night-to-night variability in AHI) Mean Difference Mean Difference Two-night Single-night Study or Subgroup Mean SD Total Mean SD Total Weight IV, Random, 95% CI IV, Random, 95% CI Ahmadi 2009 6.9 13.6 193 6.6 11.7 193 62.8% 0.30 [-2.23, 2.83] Gourveris 2010 32.72 23.1 130 33.97 23.13 130 12.7% -1.25 [-6.87, 4.37] Ma 2011 20.08 26.475 66 15.92 28.35 66 4.6% 4.16 [-5.20, 13.52] Selwa 2008 13.1 10.2 40 13.5 10.3 40 19.9% -0.40 [-4.89, 4.09] Total (95% CI) 429 100.0% 0.14 [-1.86, 2.15] 429 Heterogeneity: Tau² = 0.00; Chi² = 1.01, df = 3 (P = 0.80); I² = 0% 20 -20 -10 10 Ó Test for overall effect: Z = 0.14 (P = 0.89) Single-night Two-night

Table S66—Summary of Findings table for Two-night PSG vs. Single-night PSG for the improvement in clinical outcomes of Adults suspected of OSA

References: Ahmadi 2009 (A); Gourveris 2010 (B); Ma 2011 (C); Selwa 2008 (D)

Patient or population: Adults suspected of OSA Setting: Attended in-lab Intervention: Two-night PSG Comparison: Single-night PSG Outcomes Quality of the Anticipated absolute effects (95% CI) № of participants evidence (studies) Single-night PSG vs. second-night PSG (GRADE) AHI $\oplus \oplus \oplus \oplus$ The mean difference in AHI (variability) was 0.14 858 (4 RCTs) ^{A-D} HIGH events/h lower (-1.86 greater to 2.15 lower) with a single-night PSG.